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Background: Worldwide, colorectal cancer is the third most common malignancy. The 
development of the colorectal cancer (CRC) is a multistep process that involves e.g. an 
accumulation of mutations in tumor-growth promoting genes. In CRC, the most frequently 
found mutations are in the KRAS (30-50%) and BRAF (~10%) genes. Recent studies have 
shown that KRAS and BRAF mutations represent an important step in the development of 
carcinoma from the adenoma stage in colon cancer by affecting multiple pathways linked to the 
MAPK1, JAK-STAT, and PI3K pathways. 
A role of inflammatory cells within the tumor microenvironment and tumorigenesis is well 
established. However, the mechanism of how inflammation promotes carcinogenesis remains 
unresolved. 
As the survival and proliferation of tumor cells is influenced by immune cells within the tumor 
environment, the aim of our study was to investigate whether pro-inflammatory cytokines 
(TNFα, IL-1β and IFNγ) can induce pro- (CXCL1 and CXCL8) and anti-angiogenic (CXCL10) 
chemokines and in mutated CRC cell lines compared to wild type.  Furthermore, the behaviour 
of these chemokines in the presence/absence of the KRAS by siRNA silencing in KRAS-
mutated (DLD1) and wild type (Caco2) was analysed. 
Methods: Six colonic cell lines were investigated: DLD1 (KRAS G13D), HT-29 and Colo205 
(BRAF V600E) as well as the wild type (Wt) cell lines Caco-2, Colo-320 and CX-1. The 
presence of KRAS mutations was analysed in the cell lines by using specific mismatch primers 
to amplify genomic DNA fragments through the PCR-RFLP assay, containing the hot spots of 
codons G12D and G13D. The BRAF mutation for codon V600E was detected by real time 
PCR. DLD1, HT-29 and Caco-2 cell lines were treated with cytokines (TNFα 50ng, IL-1β 1ng 
and IFNγ 50ng) and harvested at different time points (1h-24h). KRAS inhibition was 
performed by the siRNA approach using specific nucleotide sequences in KRAS-mutant and 
wild type cell lines. Total RNA was isolated from cultured cells. Isolated RNA was converted 
into cDNA and further used for RT-PCR analysis. Similarly, protein was extracted from the 
cells to perform Western blotting. 
Results: RT-PCR analysis in non-stimulated cells showed a low basal expression of TNFα and 
IL-1ß in the KRAS mutated (DLD1) cell line, compared to wild type (Caco2). No detection was 
found for IL-6 and IFNγ in any of the studied cell lines. In contrast, pro-angiogenic chemokines 
(CXCL1, CXCL8) showed a high constitutive expression in mutated cell lines DLD1 (KRAS), 
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HT-29 and Colo205 (BRAF), compared to wild type (Caco2). However, the anti-angiogenic 
chemokine (CXCL10) showed a high basal expression in wild type, compared to mutated cell 
lines.  
Treatment with pro-inflammatory cytokines showed an induction of CXCL1 gene expression in 
mutated, and to a lesser extent in wild type cell lines at mRNA and protein level. The most 
pronounced and quick induction of CXCL1 gene expression was detected after TNFα 
stimulation in DLD1 (KRAS; 310±2.18 fold) followed by HT-29 (BRAF; 36.15±3.28 fold) 
compared to wild type (Caco2; 29.45±0.82 fold). Similar results were found after treatment 
with IL-1ß which induced the maximum gene expression of CXCL1 in HT-29 (BRAF; 
46.42±5.98 fold) followed by DLD1 (KRAS; 21.19±0.37 fold); a minor but significant increase 
was found in Caco2 (Wt; 2.6±1.6 fold).  
Likewise, CXCL8 mRNA and protein level was significantly induced by TNFα and IL-1ß in 
KRAS mutated cell line (DLD1) and wild type (Caco2). The maximum increase was observed 
in wild type (Caco2) cell line after IL-1ß treatment (806.41±19.76fold). In addition, 
administration of IFNγ significantly enhanced CXCL10 at mRNA and protein level in mutated 
cell lines HT-29 (BRAF; 15361.19±2974.33 fold) followed by DLD1 (KRAS; 597.71±64.62 
fold) in comparison to wild type (Caco2; 45.75±1.44 fold). 
In order to determine the factors responsible for chemokine induction in the downstream-
signalling pathway of pro-inflammatory cytokines, protein expression of transcription factors 
(NF-κB, MAPK1 and STAT3) involved in KRAS-mutant (DLD1) and wild type (Caco2) cell 
lines were studied. An increase in protein level of NF-κB and MAPK1 was found in both, 
mutated and wild type cell lines after cytokine stimulation. However, p-STAT-3 was only 
detected in the KRAS mutated cell line (DLD1) after IFNγ stimulation. The protein expression 
of p-STAT-3 showed a time-dependent increase up to 24 h.   
To understand the possible role of KRAS and the consequences of inhibiting its activity or 
expression in colorectal cancer cell lines, a KRAS knockdown experiment was performed in 
KRAS-mutant (DLD1) and wild type (Caco2) cell lines. KRAS was successfully knocked down 
by the siRNA technique. This down-regulation of KRAS showed a significant effect on 
chemokine gene expression: A decreased CXCL1 and CXCL10 gene expression was detected 
in the DLD1 (KRAS) cell line in comparison to wild type (Caco2) at 72h after KRAS silencing. 
In contrast, the specific KRAS inhibition resulted in an up-regulation of CXCL1 and CXCL10 
and induction of the NF-κB pathway in wild type (Caco2) cell line.  
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To summarize, basal chemokine gene expression for pro-angiogenic chemokines was high in 
mutated as compared to wild type cell lines. Furthermore, cytokine treatment induces the 
expression of pro-angiogenic (CXCL1, CXCL8) and anti-angiogenic (CXCL10) chemokines 
differentially in mutated cell lines compared to wild type. The inhibition of the KRAS resulted 
in induction of chemokines gene expression through the NF-κB pathway in wild-type cell line. 
Conclusion: This reflects the likely existence of a totally different microenvironment in tumors 
consistent of wild type or mutated cells. This may help to rationalize the choice of molecular 
targets for suitable therapeutic investigation in clinical studies. 
Key words: KRAS, BRAF, CXCL1 (GROα), CXCL10 (IP-10), CXCL8 (IL-8), TNFα, IL-1ß, 
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2. Introduction 
2.1 Colorectal Carcinoma  
Colorectal carcinoma (CRC)  is considered as one of the most common lethal cancer all over 
the world (Weitz et al. 2005). It is globally accepted that CRC is the third most common cancer 
in men and regarded as second most frequent cancer in women (Armaghany et al. 2012a)  The 
global statistics shows that it is responsible for around 529,000 deaths per year (Ferlay et al. 
2007). There have been about 20% of CRC cases which have a familial basis; (Rustgi 2007a) 
some of them are linked with well-characterized syndromes, such as hereditary nonpolyposis 
colorectal cancer and familial adenomatous polyposis (FAP). CRC is developed due to the 
uncontrolled cell growth in the colon or rectum (Karin 2006;Yu et al. 2009). It initiates from 
the crypt epithelial cells that line the colon or rectum of the gastrointestinal tract (Ionov et al. 
1993). The major causes which have been considered for CRC are environmental factors rather 
than heritable genetic changes. The most important risk factors for sporadic CRC include 
factors like food-borne mutagens, specific intestinal pathogens, chronic intestinal inflammation 
and age (Cappell 2008).  
Deregulated cell cycle control is a fundamental aspect of cancer, resulting from mutation, 
deletion and transcriptional repression of genes (Futreal et al. 2005). A loss of methyl groups in 
the DNA is found very early in colorectal tumorigenesis (Fearon and Vogelstein 
1990a;Vogelstein and Kinzler 2004). Familial adenomatous polyposis (FAP) which could lead 
to CRC, is due to inherited mutations of the adenomatous polyposis coli (APC) gene (Fearon 
and Vogelstein 1990a). Infact, APC gene plays an important role in colorectal carcinogenesis 
(Armaghany et al. 2012b). APC mutation leads to hyperproliferation  and thus has helped to 
understand early steps in CRC carcinogenesis (De et al. 2002). 
Indeed, mutations in the APC-gene trigger tumor development through the Wnt-APC-beta-
catenin pathway mutation. Furthermore, loss of the TP53 tumor-suppressor gene leads to 
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increased cell division by loss of control the cell cycle (Shaw et al. 1991). In addition, sporadic 
CRCs alter the cell signalling pathways by acquiring a change in the most common genetic 
mutations such as KRAS, BRAF (Sheng et al. 1998;Lakatos and Lakatos 2008). 
 
Figure: 1 Mechanisms of colorectal cancer (CRC) and colitis-associated (CAC).Mutations in 
the adenomatous polyposis coli gene (APC), β-catenin, and oncogenic mutations drive the 
transition of single pre-neoplastic cells to aberrant crypt-foci (ACF) and then to adenoma and 
CRC. Chronic inflammation, which leads to colitis-associated cancer, is characterized by the 
production of pro-inflammatory cytokines sustaining the inflammatory and thus tumor 
promoting microenvironment. Adapted from: (Terzic et al. 2010)  
2.2 KRAS & BRAF mutation in Colorectal Carcinoma  
The RAS and RAF family of genes code for proteins which form part of the 
Ras/Raf/MEK/ERK signalling cascade within cells (Dhomen and Marais 2007). This cascade is 
involved in the transmission of extracellular signals which control a variety of biological 
processes such as cell growth, cell survival and migration (Malumbres and Barbacid 2003).  
Disruption of this pathway, through gain-of-function mutations in RAS and RAF family 
members, is well described in several different types of cancer. In CRCs, mutations are 
frequently found in the KRAS and to a lesser extent in the BRAF (Downward 2003;Jass 2006). 
In CRC, KRAS mutations are early events (Fearon and Vogelstein 1990b;Ilyas et al. 1999) and 
 
  6  
 
are found in 30–50% of tumors (Downward 2003). KRAS mutations with different hotspots are 
identified in codons 12, 13, 61 and 146.  
In fact, the KRAS and BRAF proteins are known to be a key downstream component of EGFR 
signaling, transmitting growth-promoting EGF signals from the cell surface to the 
transcriptional machinery in the nucleus (Hanahan and Weinberg 2000). The Ras protein 
family consists of KRAS, H-Ras and N-Ras which are small GTPase proteins and are normally 
present in an inactive GDP bound form. These proteins are activated through extra-cellular 
signals from growth factors which result in phosporylation of GDP to GTP. Furthermore, these 
proteins have a serine/threonine kinase domain which is activated by Ras proteins. Activated 
Ras-protein phosphorylates MEK (MAPK/ERK kinase) which in turn phosphorylates ERK 
(extracellular signal-regulated kinase). The signal is then further transmitted through 
phosphorylation of downstream targets such as nuclear factor (NF-κB) (Dhomen and Marais 
2007).  
 
Figure: 2 EGFR signalling pathway and candidate predictive molecular markers for the 
activity of EGFR antibodies in CRC. Ligand binding and therefore dimerization of the EGFR 
monomer and activation of the EGFR pathway is inhibited by EGFR-directed antibodies. 
Adapted from: Michaela S. et al Clinical Cancer Research (2009) 
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The hotspots for mutation in G-coupled proteins such as KRAS are evolutionarily conserved 
sites, and mutation results either in a protein which is irreversibly bound to GTP (for KRAS 
codons 12,13 and 61) (Grand and Owen 1991) or in a protein which rapidly exchanges GDP for 
GTP leading to enhanced signalling activity (for KRAS codon 146) (Feig and Cooper 1988). 
Concurrent mutations are found rarely (Davies et al. 2002a;Rajagopalan et al. 2002a;Singer et 
al. 2003). Both the KRAS and BRAF undergo gain of function mutations and represent different 
modes of action of activating the same pathway. 
2.3  Colorectal Carcinoma and inflammation: role of cytokines 
 
Colitis-associated cancer (CAC) is a CRC subtype which is associated with inflammatory 
bowel disease (IBD) (Lakatos and Lakatos 2008). IBD with colon involvement is among the 
top three risk conditions for CRC (Askling et al. 2001). 20% of IBD patients which develop 
CAC within 30 years of the onset of their disease have a mortality rate of above 50% (Lakatos 
and Lakatos 2008).  
IBD exists in two major forms known as 1) Crohn‟s disease (CD) and 2) Ulcerative colitis 
(UC) (Calkins and Mendeloff 1986). IBD is deemed to be a result of continuous activation of 
the mucosal immune system. This could be due to the defects in both, barrier function of 
intestinal epithelium and the mucosal immune system (Podolsky 2002).  A failure to regulate 
normally protective cell-mediated immune responses in the intestinal mucosa result in 
sustained activation of the mucosal immune system and in uncontrolled overproduction of pro-
inflammatory cytokines and mediators (Laroux. et al. 2001). Constitutive expression of pro-
inflammatory cytokines and chemokines (Anisowicz et al. 1987a;Dubois et al. 1998) is 
hallmark of IBD (Davidson et al. 1996;McDonald et al. 1997). However, under some 
conditions immune cell subsets and cytokines fight to maintain dysplastic cells under control 
thus preventing tumor progression (Dunn et al. 2006). The role of cytokines in the mucosal 
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immune system has been studied intensively revealing that cytokines influence the nature of 
mucosal immune responses (Elson et al. 1995;Sartor 1994).  
Colorectal tumors that are not associated with clinically detectable IBD, exhibit strong 
inflammatory infiltration and increased expression of pro-inflammatory cytokines (Atreya et al. 
2008;Atreya and Neurath 2008;Clevers 2004;Waldner and Neurath 2008). Tumor cells 
themselves can produce cytokines, including IL-1α/β, IFNγ and TNF-α (Popivanova et al. 
2008) maintaining a pro-inflammatory microenvironment. They also secrete chemokines 
inducing further leukocyte infiltration. Infact, there have been efforts characterizing  immune-
cell populations and inflammatory mediators in related murine models  (Podolsky 1991). 
However, the distribution and type of inflammatory cells and role of their mediators is poorly 
described in CRC. 
Indeed, inflammatory cell (leukocytes) recruitment from the blood circulation into the tissue is 
a crucial event in the generation and maintenance of inflammatory cell infiltrates in 
inflammation. Three steps of leukocyte migration, namely tethering, rolling, and adhesion and 
crawling are involved in heterophilic interactions between one class of molecules on the 
leukocyte and another class of molecules on the endothelial cell (Muller 2003;Schenkel et al. 
2002). The process of leukocyte migration is also called trans-endothelial migration (TEM): 
diapedesis. It involves several families of cytokines (Ramadori and Armbrust 2001) and 
chemokines (Wasmuth et al. 2010). These mediators play a role in chronic inflammation. 
However, it is also unclear how immune-cell populations and inflammatory mediators 
ultimately promote chronic gut inflammation. Chronic inflammation is known to induce 
genomic mutations upon inducing DNA modifications in intestinal epithelial cells related to 
DNA methylation and histone modification (Colotta et al. 2009;Rustgi 2007b). Moreover, 
chronic inflammation results in cell proliferation, oxidative stress and ultimately in the 
development of dysplasia (Roessner et al. 2008). The mechanism of how chronic inflammation 
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develops into carcinogenesis still remains unsolved. However, it is supposed that the same 
genetic mutations which lead to sporadic CRC are also responsible for its development in IBD.  
Tumor Necrosis Factor 
A major role of cytokines released by epithelial and immune cells in colitis-associated cancer 
(CAC) is widely accepted (Popivanova et al. 2008). Tumor necrosis factor (TNF), due to its 
importance in mediating inflammation, shares many pro-inflammatory activities with the 
cytokine IL-1 (Garrity-Park et al. 2008). TNF binds to two distinct soluble receptors with 
different molecular masses of 55kDa (p-55) and 75kDa (p-75). Both soluble TNF receptors 
inhibit binding of TNF to its cellular receptors and reduce the biologic effects of TNF in a dose 
dependent manner (Loetscher et al. 1991). A previous study reported that single nucleotide 
polymorphism (SNPs) in the promoter of TNFα is associated with an increased risk for IBD 
which could lead to a genetic predisposition in the development of colitis-associated CRC 
(Garrity-Park et al. 2008) 
Interleukin-1 
Interleukin-1 is a remarkable mediator that activates many immune and inflammatory cells 
(Dinarello 1994). IL-1 is produced by monocytes/macrophages, neutrophils and endothelial 
cells (Stevens et al. 1992). It consists of IL-1α and IL-1β that bind to two types of IL-1 
receptors on their target cells, named IL-1 receptor type I and IL-1 receptor type II. IL-1 
receptor type I is responsible for the signal transduction. Effects of IL-1 are controlled by the 
IL-1 receptor antagonist, which is produced virtually by the same cells as IL-1 itself and 
competitively counteracts the actions of IL-1 (Dinarello and Thompson 1991). Previous studies 
have shown that the expression of IL-1 is increased in inflammatory lesions of patients with 
IBD (Mahida et al. 1989;Rogler and Andus 1998a). IL-1 receptor antagonist is increased as 
well, but not to the same extent as IL-1. This results in a local imbalance between IL-1 and IL-1 
receptor antagonist in the inflamed mucosa (Rogler and Andus 1998a;Andus et al. 1997;Casini-
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Raggi et al. 1995). It is known that the macrophages are the main producer of IL-1 in the 
inflamed mucosa. However, IL-1 receptor antagonist seems to be an important source in the 
intestinal epithelial cells (Rogler and Andus 1998a). 
Interferons 
Type I interferons comprise two different groups of proteins. The first group is interferon α 
(IFNα) that comprises a family of about 20 structurally related polypeptides of approximately 
18-kDa. The interferons are mainly produced by mononuclear phagocytes (Breese et al. 1993). 
Type II interferon, also called IFNγ or immune IFN, is a homo dimeric glycoprotein containing 
21-to 24-kDa subunits. It is produced by Th1 lymphocytes and NK cells. IFNγ binds to a 
receptor different from that utilized by type I interferons. It is anti-viral and anti-proliferative 
and one of the most potent activators of mononuclear phagocytes, increases MHC class I and II 
expression, promotes T and B cell differentiation, and activates neutrophils, NK cells, and 
vascular endothelial cells (Langaas et al. 2001) . In Crohn‟s disease IFNα and especially IFNγ 
have been found to be elevated in the intestinal mucosa (Breese et al. 1993;Fais et al. 1991). 
 
Figure 3:  Intestinal immune response to enteric antigens. Effector CD4+ T cells produce T 
helper-1 (Th1)-type cytokines in response to processed and presented antigen by antigen-
presenting cells (APCs). These cytokines may affect the gut epithelium directly and/or 
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activate resident macrophages (M ) to release large amounts of pro-inflammatory 
mediators: cytokines as well as reactive metabolites of oxygen (ROS) and nitric oxide (NO). 
The net result is the recruitment of additional leukocytes and subsequent tissue injury. 
Modified from (Laroux et al. 2001). 
2.4  Role of Chemokines in Colorectal Carcinoma  
 
Chemo-attractant cytokines play a key role in the modulation of the immune system (Aggarwal 
and Pocsik 1992). They can induce or increase the synthesis of many structural and secretory 
proteins, (Malik et al. 2011;Ramadori and Christ 1999;Ramadori et al. 2008) including 
chemokines.  Furthermore, they also help in the infiltrating process of inflammatory cells, 
recruited from the blood by chemokine mediators released at the site of damage (Malik et al. 
2010). In turn, inflammatory cells are responsible for production of cytokines (IL-6, IL-1β, TNF-
α and IFN-γ), which are released into the blood (Malik et al. 2011;Ramadori and Christ 
1999;Ramadori and Armbrust 2001) and can act distantly on intact organs (Malik et al. 2011).   
Chemokines are thought to be responsible for recruiting inflammatory cells. They are actively 
involved in inflammation, tissue repair, development of fibrosis and tumor (Malik et al. 
2010;Marra 2002;Owen et al. 1997). Chemokines, comprise a set of low-molecular weight 
cytokines (7-10 kDa), which play a key role in  directing migration and activation of leukocytes 
in the inflammatory processes (Macdermott 1999).  Based on their primary structure, 
chemokines are distinguished as C, CC, CXC or CX3C where “X” represents a non conserved 
amino acids substitution. Apart, from „C‟ –subgroups, all chemokines consists of a four cystine 
residue motif which is linked by disulfide bonds in the conserved region for the formation of 
the ß-sheet structures (Fernandez and Lolis 2002). The chemokine nomenclature named the 
receptor „R‟ like in CXCR1 and the respective ligand „L‟ as in CXCL8. The chemokines are 
secreted by both, the stromal and malignant part of the cancer tissue. Functionally, the 
chemokine ligand and receptor pairs can exert a direct effect on tumor proliferation and 
survival (Boimel et al. 2012;Erreni et al. 2009). It is possible that the chemokines from stromal 
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cells may influence the survival of malignant cells by binding to the functional receptors 
acquired on the cancerous cells, which increases metastasis in a chemokine rich environment 
(Balkwill 2012;Mantovani et al. 2010).  
Several studies have been published to elucidate the dual role of chemokines in promotion and 
inhibition of angiogenesis (Kiefer and Siekmann 2011;Keeley et al. 2008). The CXC 
chemokines which regulate angiogenesis CXCL1 and CXCL8 have strong effect in tumor 
angiogenesis, on the other side, CXCL10 inhibits neo-vascularisation (Belperio et al. 
2000;Moore et al. 1998;Rossi and Zlotnik 2000;Wang et al. 1998).   
CXCL1/GROα  
CXCL1 belongs to the CXC chemokine family which was previously named KC, GRO1, 
GROα, and MSGA-α. This chemokine is secreted by melanoma cells in human, has mutagenic 
properties and is implicated in pathogenesis (Anisowicz et al. 1987b;Richmond and Thomas 
1988). Moreover, it is highly expressed by macrophages, neutrophils and epithelial cells 
(Becker et al. 1994;Iida and Grotendorst 1990) and has a role in the neutrophil chemo-attractant 
activity (Moser et al. 1990;Schumacher et al. 1992). CXCL1 exerts its effects by signaling 
through the chemokine receptor CXCR2 (Tsai et al. 2002). Previously in vitro and in vivo 
studies have shown that exogenous PGE2 (Prostaglandin E2) induces CXCL1 expression and 
release from CRC cells. The induction of CXCL1 by PGE2 is dose dependent and activates the 
epidermal growth factor receptor (EGFR)-mitogen activated protein kinase (MAPK) pathway 
(Wang et al. 2006). 
CXCL 8/ IL 8 Interleukin-8 
CXCL8 is a soluble small peptide of 8-10kDa (Baggiolini et al. 1992). Myriad cell types 
secrete CXCL8 chemokine including intestinal epithelial cells. Its two commonly known 
homologous receptors CXCR1 and CXCR2 binds to its ligand CXCL8 with high affinity 
(Fusunyan et al. 1998;Kim et al. 2001;Holmes et al. 2009;Murphy et al. 2000). CXCL8 is 
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considered to be one of the prototype among the chemokines that has chemotactic activities, is 
secreted by monocytes and macrophages and assists in the directive migration of neutrophils, 
basophils and T-lymphocytes (Baggiolini et al. 1992;Rossi and Zlotnik 2000). It has an active 
role in the recruitment and transmigration in the inflammation locus (Struyf et al. 2005). 
CXCL8 induces neutrophils to secrete lysosomal enzymes, change shape and adhesion to 
endothelial cells (Hoch et al. 1996). Prior studies have shown that TNF and  IL-1 induce 
CXCL8 expression in human monocytes and lymphocytes (Chaly et al. 2000). The exact role 
and actual mechanisms of CXCL8 mRNA and protein expression as well as the effect of 
different cytokines on the expression and secretion of CXCL8 in colorectal carcinoma is still 
unclear.  
CXCL10(IP-10/) Interferon-gamma activated protein  
CXCL10 which represents CXC chemokines is the human interferon inducible protein 10 (Liu 
et al. 2011b). CXCL10 is originally known as an interferon (IFN) inducible gene and due to its 
high affinity receptor CXCR3 (Dwinell et al. 2001). CXCL10 is constitutively produced by 
intestinal epithelial cells after stimulation with IFNγ (Gasperini et al. 1999). It is mostly 
expressed through activation of CD4
+
 memory T cells that produce a Th1 cell pattern of 
cytokines (Loetscher et al. 1991;Qin et al. 1998). Previous studies examined that stimulation 
with pro-inflammatory cytokines enhances the expression of CXCL10 in intestinal epithelial 
cells in vitro (Dwinell et al. 2001). It is also reported that CXCL10 is responsible for the 
inhibition of cell proliferation and induces apoptosis in endothelial cells (Loetscher et al. 
1991;Feldman et al. 2006). Basically CXCL10 shows a minor production in the colon, 
however, in abnormal conditions a significant enhancement of the expression is detected in the 
colonic lamina propria of biopsied specimen of ulcerative colitis (UC) patients (Uguccioni et al. 
1999).  
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Figure 4: Immunosurveillance and inflammation in colorectal cancer (CRC) and colitis 
associated cancer (CAC). Innate and adaptive immune cells promote tumor development. 
Inflammation can promote colitis-induced tumorigenesis. In sporadic CRC, the balance of 
immune cells may be shifted towards tumor-promoting inflammation. DC, dendritic cells; 
NK, natural killer cells. Adapted from: (Terzic et al. 2010). 
2.5 Role of Transcription Factors in colorectal carcinoma 
The identification of signalling pathways within tumor cells that eventually induce tumor 
growth or suppress anti-tumor immunity is a significant challenge (Bollrath and Greten 2009). 
To understand these complex interactions could help to identify targets for the cancer treatment 
and prevention. A large percentage of CRCs and cell lines reveal a constitutive activation of 
transcription factors that are important components of multiple inflammatory pathways, namely 
nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) 
(Sakamoto et al. 2009;Yu et al. 2009). 
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Figure 5:   JAK and STAT are critical components of many cytokine receptor systems. Jaks 
and Stats are critical components of many cytokine receptor systems, regulating growth, 
survival, differentiation and pathogen resistance. An example of these pathways is shown 
for the IL-6 (or gp130) family of receptors, which co-regulate B cell differentiation, plasma 
cytogenesis and the acute phase reaction. Cytokine binding induces receptor dimerization, 
activating the associated Jaks, which phosphorylate themselves and the receptor. The 
phosphorylated sites on the receptor and Jak serve as docking sites for the SH2-containing 
Stats, such as Stat3, and for SH2-containing proteins and adaptors that link the receptor to 
MAP kinase, PI3K/Akt, and other cellular pathways. Adapted from: Cell Signalling 
Technology (2010) 
NF- B occurs as a heterodimer which consists of five subunit members: p105/p50, p100/p52, 
RelA (p65), c-Rel, and RelB (Ruben et al. 1992). In the classical NF- B pathway, these family 
subunit members are passive in the cytoplasm and bound to specific inhibitors like κB (IκB) 
proteins. It is reported that the classic mechanisms of NF-κB activation occur in colitis 
associated cancer (CAC) and colorectal carcinoma (CRC) and include signalling by pattern 
recognition receptors and by tumor-promoting cytokines like TNF, IL-1 and IL-17 (Karin 
2006). NF- B transcriptionally activates many genes involved in cell function which are 
responsible in early inflammatory responses comprising CXCL8, iNOS, TNF- , IL-1 , IL-6, 
COX-2(Baldwin, Jr. 1996;Grilli and Memo 1999). Some studies have also revealed that NF- B 
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could be a main regulator in chemokine gene expression and a key regulator in neutrophil 
migration when intestinal epithelial cells were stimulated with Bacteroides fragilis enterotoxin 
(Kim et al. 2002). 
Several oncogene products that can activate NF-κB have been identified such as ras (Finco and 
Baldwin, Jr. 1993). It is reported that oncogenic RAS increases NF-κB transcriptional activity 
through RAF dependent and RAF-independent mitogen-activated protein kinase signaling 
pathways (Norris and Baldwin, Jr. 1999). In colorectal carcinoma and in particular Ulcerative 
Colitis and Crohn‟s disease the enhancement of NFκB activation prevail in IECs together with 
macrophages (Andresen et al. 2005;Jobin et al. 1997;Rogler and Andus 1998b).  
 
 
Figure 6:  Mechanism of NF- B activation and regulation. NF- B is kept latent in the 
cytoplasm by the inhibitor protein I B.  I B phosphorylation leads to ubiquitination and 
degradation by the proteasome pathway. Free RelA (p65) migrates to the nucleaus and by 
virtue of its nuclear localization activates transcription of multiple kB-dependent genes. IL-
interleukin; TNF, tumor necrosis factor; LPS, lipopolysaccharide. Adapted from: (Jobin et 
al. 1997). 
Another important transcription factor in inflammatory pathways is STAT3 (Darnell, Jr. 
2007;Schindler 2002). It is activated through phosphorylation of tyrosine 705, in response to 
various cytokines and growth factors including interferons, epidermal growth factor,  
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Interleukin-6 and hepatocyte growth factor. For STAT3 a constitutive activation in primary 
human colorectal carcinoma cells and established human colorectal cancer cell lines has been 
shown (Corvinus et al. 2005;Kusaba et al. 2005;Ma et al. 2004). Constitutive STAT3 activation 
in colorectal cancer cells is associated with invasion, survival, and growth of colorectal cancer 
cells and colorectal tumor model in mice in vivo (Corvinus et al. 2005;Lin et al. 2005;Tsareva 
et al. 2007;Xiong et al. 2008). In fact, STAT3 was shown to have an oncogenic or tumor 
suppressor role depending on the mutational background of the tumor. Moreover, its role as a 
tumor suppressor gene has also been reported (de la Iglesia et al. 2008). STAT3 is a vital 
oncogenic pathway activator in colorectal cancer and can serve as a potential therapeutic target 
for colorectal carcinoma (Lin et al. 2011). 
 
Figure 7:  Signal transducers and activators of transcription (STAT) are activated by 
cytokine and growth factor receptors. Involvement of cytokines and transcription factors in 
tumor promotion: Cytokines and growth factors in the tumor microenvironment activate 
transcription factors such as NF-κB, STAT3, and AP-1, which regulate genes that control 
numerous processes such as cell proliferation, tumor growth, and resistance to cell death, 
angiogenesis and tumor progression and invasion. Adapted from: (Terzic et al. 2010).  
 
 18  
 
2.6 Treatment selection in Colorectal Carcinoma 
The four main types of treatment for colorectal cancer are surgery, radiation therapy, 
chemotherapy and targeted therapies (like monoclonal antibodies).  
KRAS gene somatic mutations at codon 12 and 13 occur with an incidence of 30 to 40% in 
CRC (Downward 2003). KRAS is the central mediator of epidermal growth factor receptor 
(EGFR) signalling, it is reasonable to suggest that the KRAS mutational status might modify 
the response of a tumor to anti-EGFR therapy (Feng et al. 2007). Cetuximab (Erbitux) and 
Panitumumab (Vectibix), monoclonal antibodies directed against EGFR, are commonly used to 
treat metastatic CRC.  They inhibit the signal from the EGFR and block downstream effects 
including BRAF and KRAS-mediated events. Whenever KRAS and BRAF mutations exist, the 
RAS-RAF-MEK-ERK signaling pathway remains in the “on” state leading to continuous cell 
division and proliferation (Cunningham et al. 2004;Zhang et al. 2006). Tumors with mutant 
KRAS genes may not respond to Cetuximab but they are still receptive to chemotherapy and 
research is in progress to develop drugs which will boost the efficacy of chemotherapy for 
these tumor types.  
Anti-TNF therapy is a new class of biological therapy (Garces et al. 2012) that inhibits TNF 
released by macrophages which augments rheumatoid arthritis (RA) and inflammatory bowel 
disease (IBD) such as Crohn‟s disease and ulcerative colitis (Atzeni et al. 2011). Three types 
of anti-TNF therapy are used so far: etanercept (Enbrel®), infliximab (Remicade®) and 
adalimumab (Humira®). Many studies revealed that infliximab has made a significant 
progress in therapy for patients with Crohn‟s disease (van Dullemen et al. 1995). The 
efficiency of infliximab suggests that TNF, a product of activated macrophages, could have a 
major role among the many regulatory peptides with altered expression in association with 
IBD (Lugering et al. 2001;Ten et al. 2002). 
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2.7 Aims of study  
A major contributor to the tumor microenvironment is inflammation and inflammatory 
mediators (especially the cytokines IL-1β, IFNγ and TNFα). There have been studies about the 
effect of cytokines on chemokine gene expression and cross talk between EGFR and 
chemokines. However, little is known about the effect of these mediators on gene expression of 
chemokines (CXCL1, CXCL8 and CXCL10) in the presence/absence of KRAS mutation.  
Based on these studies, we hypothesized that stromal cells of the tumor microenvironment may 
release pro-inflammatory cytokines (IL-1β, IFNγ, and TNFα) and EGF which in turn acts on 
CRC-cells to secrete chemokines (CXCL1, CXCL8 and CXCL10). These chemokines in turn 
attract inflammatory cells which act on the tumor cell and its microenvironment, thereby 
multiplying the inflammatory effects and subsequent tumor initiation and promotion. 
The inhibition of these pro-inflammatory and angiogenic pathways may lead to new insights 
into new drug development discoveries for the KRAS and BRAF mutated patients who are 
irresponsive to anti EGFR therapies. This study is based on the findings that KRAS and BRAF 
mutations in CRCs are considered mutually exclusive in the activation of the 
RAS/RAF/MEK/ERK pathway. In view of this knowledge, six CRC cell lines were 
investigated for their mutation and regulation of pro- (CXCL1 & CXCL8) and anti-angiogenic 
(CXCL10) chemokine gene expression. By adding pro-inflammatory cytokines to the medium, 
a different microenvironment was created. Moreover, it was also the aim of study to investigate 
the transcriptional factors which are involved in the regulation of these chemokines in CRC 
mutated and non-mutated cell lines after administration of pro-inflammatory cytokines (TNFα, 
IFNγ and IL-1ß).  
 Aims of the project:   
1.  To validate the previously published KRAS (12, 13, 61, 146), BRAF (V600E) and 
 NRAS (12, 61) mutations in the six CRC cell lines. 
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2.    To investigate the cytokine (TNFα, IFNγ and IL1ß) / chemokine (CXCL1, CXCL8 & 
CXCL10) profile in view of the different mutations of the CRC cell lines. 
3.   To understand the effect of cytokines (TNFα, IFNγ and IL1ß) on pro- and anti- 
angiogenic chemokines in CRC mutated and wild type cell lines. 
4. To explore the role of these chemokines and their signalling pathway by knocking down 
the KRAS-gene in mutant (DLD1) and wild type (Caco2) colorectal cancer cell lines.  
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3. MATERIALS AND METHODS 
 3.1 Materials 
3.1.1. Laboratory devices 
 
Applied Bio-System PRISM® 7000 Sequence Detection System (ABI, USA) 
Centrifuge Hettich Rotixa/K (Hettich Zentrifugen) 
DNA Engine System 9600 (Gene Amp Perkin Elmer) 
Electro blotting apparatus, type Mini Trans-BlotR, Bio-Rad /Munich, Germany 
Electrophoresis apparatus, type Mini-ProteanR III, Bio-Rad /Munich, Germany 
GeneQuant RNA/DNA Calculator (Pharmacia, Freiburg) 
Heraeus Laminair (Heraeus Instruments GmbH, Hanau) 
Heraeus Thermostat (Heraeus Instruments GmbH, Hanau) 
Horizontal Gel Electrophoresis Apparatus HORIZON 11·14 (GIBCO BRL, Grand Island) 
Ice machine, Ziegra /Isernhagen, Germany 
Minishaker Bioshaker BD (BioRad,Goettingen) 
Microscope Leica, DMIL  (Oberkochen, Germany) 
Microwave oven, Siemens /Germany 
pH-Meter 761 Calimatic, Knick (Berlin, Germany) 
Power supply PowerPac 300 (Bio-Rad, Hercules) 
Power supply PowerPac 200 (Bio-Rad, Hercules) 
Precisious scale Sartorius (Sartorius AG, Goettingen) 
Ready Gel Cell (Bio-Rad, Hercules) 
StepOnePlus
TM
Real-Time PCR System Applied Biosystems (ABI, USA) 
Shaking platform Heidolph Polimax 2040 (Heidolph) 
Stratalinker™ 180 system (Stratagene, La Jolla) 
Thermomixer comfort (Eppendorf-Netheler-Hinz GmbH, Hamburg) 
Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules) 
Transilluminator 2020E (Stratagene, La Jolla) 
Video Densitometer (Herlob, Wiesloch, Germany) 
Water bath 1083, GFL (Burgwedel, Germany) 
X-ray film cassettes 10×18, (Siemens /Germany) 
X-ray film-developing machine SRX-101A, Konica Europe (Hohenbrunn, Germany) 
 
 




6 well plates       (Nunc, Rushilde) 
24 well plates       (Nunc, Rushilde) 
75 cm culture flasks     (Nunc, Rushilde) 
Siemens film cassette     (Siemen, Germany) 
Eppendorf tubes      (Eppendorf-Netheler-HinzGmbH, Hamburg) 
Nitrocellulose membrane     (Novex, Frankfurt) 
Pharmacia NICK Column     (Pharmacia Biotech) 
QIAshredder       (QIAGEN GmbH, Hilden) 
Tissue culture dishes (60/15 mm, Cellstar)   (Greiner GmbH, Frickenhausen) 
X-OMAT autoradiography film    (Eastman Kodak Company, Rochester) 
3.1.3. Cells 
 
Caco2, HT-29, DLD1 Colo-320, Colo-205 and CX-1 were from human colon adenocarcinoma 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig). Some 
cell lines were cultured and used for positive control i.e. EGI-1, SW-948 and ML-2. 
3.1.4. Chemicals 
 
1, 4-dithiothreitol /DTT     (GIBCO BRL, Grand Island) 
2‟-deoxynucleoside5‟-triphosphates/dNTPMix  (Roche Molecular Biochemicals, 
Mannheim) 
2-mercaptoethanol      (Merck KGaA, Darmstadt) 
2-propanol       (Merck KGaA, Darmstadt) 
Acrylamide       (Sigma-Aldrich, Deisenhofen) 
Agarose       (GIBCO BRL, Grand Island) 
Albumin / from bovine serum, fatty acid free/   (Roche Molecular Biochemicals, 
Mannheim) 
Albumin /from bovine serum/    (Bio-Rad, Hercules) 
Aminoacetic acid /glycin/     (Sigma-Aldrich, Deisenhofen) 
Ammonium persulfate     (Sigma-Aldrich, Deisenhofen) 
Ampicillin       (Sigma-Aldrich, Deisenhofen) 
Ampuwa water      (Fresenius /Bad Homburg, 
Germany) 
Bis-acrylamide      (Sigma-Aldrich, Deisenhofen) 
BstX1 Enzyme      (New England Bio-Labs) 
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β-Glycero Phosphate      (Sigma-Aldrich, Deisenhofen) 
Dimethyl Sulphoxide /DMSO/    (Sigma-Aldrich, Deisenhofen) 
Di-Sodium hydrogen phosphate /Na2HPO4/  (Merck KGaA, Darmstadt) 
Eagle‟s minimal essential medium /EMEM/   (BioWhittaker, Verniers) 
Ethanol absolut      (Merck KGaA, Darmstadt) 
Ethidium bromide      (Sigma-Aldrich, Deisenhofen) 
Ethylenediaminetetraacetic acid /EDTA/   (Sigma-Aldrich, Deisenhofen) 
Edetate disodium Na2 EDTA     (Sigma-Aldrich, Deisenhofen) 
Ethyleneglycol-bis( -aminoethylether)N,N,N‟,N‟-tetraacetic 
acid /EGTA/       (Sigma-Aldrich, Deisenhofen) 
Fetal calf serum (FCS)     (GIBCO BRL Grand Island) 
Hydrochloric acid /HCl     (Merck KGaA, Darmstadt) 
Interferon /human      (Roche Molecular Biochemicals, Mannheim) 
Interleukin-1 /human     (Roche Molecular Biochemicals, 
Mannheim) 
Leupeptin       (Sigma-Aldrich, Deisenhofen) 
Magnesium sulphate /MgSO4    (Merck KGaA, Darmstadt) 
Magnesium Chloride /MgCl2     (Merck KGaA, Darmstadt) 
Methanol       (Merck KGaA, Darmstadt) 
Moloney Murine Leukemia Virus Reverse  
Sodium orthovanadate/ Na3VO4    (Sigma-Aldrich, Deisenhofen) 
Sodium Chloride/NaCl     (Sigma-Aldrich, Deisenhofen) 
Transcriptase /M-MLV-RT/     (Roche Molecular Biochemicals, Mannheim) 
N-2 (hydroxyethyl) piperazine-N‟- 
(2-ethanesulfonic acid)/HEPES/    (Sigma-Aldrich, Deisenhofen) 
Nonidet NP-40      (Sigma-Aldrich, Deisenhofen) 
Penicillin/Streptomycin     (GIBCO BRL Grand Island) 
Phenylmethansulfonyl fluoride /PMSF/   (Sigma-Aldrich, Deisenhofen) 
Phosphate buffered saline /PBS    (Bio-Chrome AG, Berlin) 
Potassium chloride /KCl/     (Merck KGaA, Darmstadt) 
Potassium dihydrogen phosphate /KH2PO4/  (Merck KGaA, Darmstadt) 
Primer for cDNA Synthesis /p(dT)15/   (Roche Molecular Biochemicals, 
Mannheim) 
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Pyrolidinedithiocarbamate/PDTC    (Sigma-Aldrich, Deisenhofen) 
RPMI-1640       (BioWhittaker, Verniers) 
Sodium acetate      (Sigma-Aldrich, Deisenhofen) 
Sodium citrate      (Sigma-Aldrich, Deisenhofen) 
Sodium chloride (NaCl)     (Merck KGaA, Darmstadt) 
Sodium dodecyl sulphate (SDS)    (Sigma-Aldrich, Deisenhofen) 
Sodium hydroxide solution (NaOH)    (Merck KGaA, Darmstadt) 
Sodium pyruvate      (GIBCO BRL Grand Island) 
Sodium Pyrophosphate tetra basic dehydrate   (Sigma-Aldrich, Deisenhofen) 
Tumor Necrosis Factor (human)    (Roche Molecular Biochemicals, 
Mannheim) 
TEMED/N, N, N‟, N‟,-Tetramethyl ethylenediamine (Sigma-Aldrich, Deisenhofen) 
Trypsin/EDTA                 (BioWhittaker, Verniers) 
Triton X-100 4-(1, 1, 3, 3-Tetramethylbutyl) phenyl-polyethylene glycol t-
Octylphenoxypolyethoxyethanol Polyethylene glycol tert-octylphenyl ether (Sigma-
Aldrich, Deisenhofen) 
Trypan blue       (Biochrom /Berlin) 
Tween 20       (Bio-Rad /Munich) 
Xcm1 Enzyme                (New England BioLabs) 
QuikHyb
® 




Restriction Digest Buffer 2 (Xcm1): 
1X NEBuffer 2:  
Tris-HCl  50 mM  
NaCl   100 mM 
MgCl2   10 mM  
DTT   1 mM 
pH    7.9 @ 25°C 
 
Restriction Digest Buffer 3 (BstXI): 
1X NEBuffer 3:  
Tris-HCl  50 mM  
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NaCl   100 mM 
MgCl2   10 mM  
DTT   1 mM 
pH    7.9 @ 25°C 
 
Agarose gel 1.5 % (In TBE buffer): 
Agarose   1.5 % (w/v) 
Ethidium bromide  0.4 µg/ml 
 
Extraction Buffer for protein isolation (In Distilled H2O): 
HEPES   pH 7.9 20 mM 
KCl    10 mM 
EDTA   0.1 mM 
DTT    1mM 
PMSF    0.5 mM 
Extraction buffer with NaCl for protein isolation (In Distilled H2O): 
HEPES   pH 7.9 20 mM 
NaCl    0.4 M 
EDTA   0.1 mM 
DTT    1mM 
PMSF    0.5 mM 
Triton X-100 Lysis Buffer (Cell Signalling): 
Tris-HCl   pH 7.5 
NaCl    150mM 
Na2 EDTA   1 mM 
EDTA   1mM 
Triton    1% 
Sodium Pyrophosphate 2.5mM 
β-Glycero Phosphate  1mM 
Na3VO4   1mM 
Leupeptin   1μg/ml 
TBE-buffer (10X) (In Distilled H2O): 
Tris base   0.1 M 
Boric acid   0.1 M 
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EDTA  pH 8   1 mM 
Loading buffer (In distilled water and stored for 2-3 months at –20°C): 
Running buffer   5 ml 
2ß- Mercaptoethanol 40μl 
Bromophenol blue  10mg 
Blocking buffer (In TBS-T) 
Dried Milk     5%  
Stripping Buffer (In distilled H2O) 
Tris-HCL (pH 7)   50mM  
SDS   2% 
DTT    50mM  
3.1.6.  Kits 
 
RNeasy Mini Kit     (QIAGEN GmbH, Hilden) 
DNA/RNA All Prep Mini Kit  (QIAGEN GmbH, Hilden) 
 
3.2. Methods 
3.2.1 Cell culture conditions and Stimulation. 
 
Caco-2 and CX-1 cells were grown in DMEM medium containing 20% FCS for Caco2 and 
10% for CX-1 supplemented with 100 U/ml each penicillin and streptomycin and 1% non 
essential amino acids at 37°C and 5% CO2. HT-29, Colo-205, Colo-320 and DLD1 were grown 
in RPMI medium containing 10% FCS and 100U/ml penicillin and streptomycin at 37
o
C and 
5% CO2. Intestinal Epithelial Cells (IECs) cells were cultured in combination of Dulbecco`s 
MEM and RPMI 1640 (1:1) containing 10 % FCS, 1 % sodium pyruvate, 100 U/ml penicillin 
and 100 U/ml streptomycin at 37 °C under an atmosphere of 5 % CO2. For cytokine 
stimulation, IECs were plated into 6-well plates at a density of 5 10
5 
cells per well and grown 
till they reached 70-80% confluence. These cells were then stimulated with IL-1  (1 ng/ml), 
TNF  (50ng/ml) and IFN  (50ng/ml) based on the type of experiments. 
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3.2.2 Primers for real-time PCR. 
Table1: List of Human Primers Sequences used for Real Time PCRs.  
3.2.3.  Purification of genomic DNA 
 
DNA isolation was performed using the Qiagen DNA/RNA all Prep Mini Kit according to the 
manufacturer‟s recommendations (Qiagen, Hilden,Germany). Colorectal Carcinoma cells 
(5x10
4
) were washed and resuspended with 3ml PBS then lysed in 350µl highly denaturing 
guanidinium isothiocyanate-containing buffer (Buffer RLT). RNases were inactivated by 
adding -mercaptoethanol to the buffer previously (10µl/1ml Buffer RLT). The lysate was 
pipetted directly onto a QIAshredder column sitting in the 2ml collection tube and centrifuged 
for 2 minutes at maximum speed to homogenize. 350µl of 70% ethanol was added to the 
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homogenized lysate to provide appropriate binding conditions and mixed well by pipetting. The 
amount of isolated DNA was determined Spectrophotometrically (GeneQuantII; Pharmacia, 
Freiburg, Germany). 
 
3.2.4 Anti bodies for Western Blot Analysis 
Table2: List of Human Antibodies used for Western Blot Analysis.  
 
3.2.5.  KRAS Mutation  
 
KRAS Mutations at codons 12 and 13 were confirmed in all six cell lines by a highly sensitive 
PCR-RFLP assay (Fig. 7). 10ng of DNA were used as template for the first PCR, which 
consisted volume of containing Taq DNA polymerase, deoxynucleotide triphosphates , reaction 
buffer Buffer including MgCl2; Invitrogen), and the oligo-nucleotide primers Ras A and Ras B 
(3μM each for the first PCR). The first PCR generated an amplicon of 166-bp length. For 
amplification, a DNA Engine System 9600 (Gene Amp Perkin Elmer) thermocycler was used. 
Cycling conditions of the first PCR were as follows: initial denaturation (5 min at 95°C), 
followed by 30 cycles of denaturation (1 min at 94°C), annealing (50sec at 50°C), and 
elongation (50sec at 72°C). After the last cycle, a final extension (10 min at 72°C) was added, 
and thereafter, the samples were kept at 4°C. The Ras A (sense) primer is designed to introduce 
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a restriction site for BstXI and XcmI into the wild-type amplicon. Because of this altered 
sequence, BstXI restricted the resulting amplicon if the first two bases of codon 12 were wild 
type. Similarly, XcmI cut the amplicon only, if the first two bases of codon 13 were wild type 
(Table. 2 & Figure. 8).  
For the first PCR restriction, 10μl from the first PCR reaction were digested with five units of 
either BstXI or XcmI in a total volume of 20μl, according to the manufacturer's 
recommendations (New England Biolabs, Schwalbach, Germany). 2.5μl of this first digest 
were used as template for the second PCR, in which primer Ras C (antisense)  was used instead 
of Ras B ,thus creating a restriction site in both mutant and wild-type amplicons for enzymes 
BstXI or XcmI. The PCR was run under the same conditions as the first PCR for 32 cycles. For 
the second restriction, 10μl of the second PCR were digested with five units of either BstXI or 
XcmI in a volume of 20μl. 10μl of the product were run on a 4% Agarose Gel (Roth,Karlsruhe, 
Germany) with ethidium bromide for 1 min, and analyzed under UV light by a video 
densitometer (Herolab, Wiesloch, Germany). The DNA bands were visualised for the codon 12 
and 13 with positive controls according to the base pairs of the specific positive controls band. 
Amplicons of mutated DNA were cut only once into fragments of 134 and 18bp, whereas 
amplicons of wild-type DNA were cut twice into bands of 106, 28 and 18bp length.  A positive 
control DNA (5μg) from MDA-MB-231(For Codon 13) (Health Protection Agency Culture 
Collections UK) and positive cell lines EGi-I (For Codon 12) was used as a standard to control 
the efficacy of the restriction enzymes. Autoclaved, double deionized water was used as 
negative control. 
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Figure 8:  Restriction Length Polymorphism RFLP PCR Schematic two step assay for KRAS 
detection at codon G12D and G13D with restriction enzymes BstXI or XcmI. Source: 














 31  
 
Table3: Reaction Setup and Running Protocol of RFLP PCR with two   
 Restriction Enzymes (BstX1 & Xcm1).   
 
In the table above the reaction setup, running protocol and digestion is shown for PCR1 and 
Digestion 1. The PCR2 set up and digestion2 is conducted in the same manner except the 







 step was done with 32 cycles.  
3.2.6.  BRAF Mutation  
 
Braf Mutations at codons V600E were confirmed in all six cell lines by Real Time ARMS PCR 
method (Table. 5). For each PCR, 1 μL template DNA( 6.4ng/μl) was mixed with 5 μL (2× 
SYBR Green) PCR master mix and 3μM each of the forward (A or T) and reverse primers in a 
final volume of 10 μL. One was the standard protocol of the ABI Prism 7000 Sequence 
Detection System, 2min at 95°C annealing temperature, 15s at 95°C with 30s at 60°C for 45 
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cycles, and followed by the thermal denaturing step to generate the dissociation curves to verify 
amplification specificity (Table. 5).  
For the ARMS PCR assay an additional standard curve, serial 10-fold dilutions (range 2:0–
1:1024) of the positive control (Colo-205) mixed into negative control (A212XI) were 
constructed from each dilution used to generate standard comparison curves against which to 
compare the unknown cancer cell lines. Each reaction contained in a 10μl reaction volume as 
stated above. Reactions were run for 45 cycles (95°C for 15s initiation, then 60°C 1min, 95°C 
15s) on a 96-well plate using an Applied Biosystems 7700 Sequence detector (Applied 
Biosystems, CA, USA). All samples were run in duplicate, and were run concurrently on the 
same plate. Each plate also included multiple water blanks as an additional negative control 
(Table. 5).The same method is used for the confirmation of single nucleotide for KRAS A61T and 
A146T (Sequence not mentioned). 
 
Figure 9:  Schematic presentation of the tetra- Primer ARMS-PCR method. The single 
nucleotide polymorphism used here as an example is a G→A substitution, but the method 
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Table4: Reaction Setup and Running Protocol of ARMS PCR with Standard 
  Curve.   
 
3.2.7.  RNA isolation 
 
Colo-205, Colo-320, CX-1, Caco-2, HT-29 and DLD1 cells were cultured in 6 well tissue 
culture plates at a density of 5x10
5
/well in 2 ml medium. 24 hours after seeding cells, they were 
incubated with different concentrations of IL-1 , TNF , and IFN . Total RNA was isolated by 
using Qiagen RNeasy mini kit. The cells were first washed with 3ml PBS then lysed in 350µl 
highly denaturing guanidinium isothiocyanate-containing buffer (Buffer RLT). RNases were 
inactivated by adding -mercaptoethanol to the buffer (10µl/1ml Buffer RLT). The lysate was 
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pipetted directly onto a QIAshredder column sitting in the 2ml collection tube and centrifuged 
for 2 minutes at maximum speed to homogenize. 350µl of 70% ethanol was added to the 
homogenized lysate to provide appropriate binding conditions and mixed well by pipetting. The 
lysate was applied to an RNeasy spin column and centrifuged for 1 minute at 10000 rpm. The 
membrane-bound RNA was washed first by pipetting 500 µl washing buffer (Buffer RW1) than 
by adding 500 µl ethanol containing Buffer RPE onto the column and centrifuging for 1 min at 
10000 rpm. The RNeasy membrane was dried by 500 µl Buffer RPE centrifuging for 2 min at 
maximum speed and the column was transferred to a 1.5 ml Eppendorf tube. 30µl RNase-free 
water was added to the membrane and the RNA was eluted by centrifuging for 1 min at 10000 
rpm. The total RNA was stored at –80 °C.The concentration of total RNA was determined by 
spectrophotometry measuring the absorbance at 260 and 280 nm. (An absorbance of 1 unit at 
260 nm corresponds to 40 µg RNA per ml. This relationship is valid for measurements of 
water-diluted RNA).  
3.2.8.  Reverse Transcription & Real-Time PCR 
 
RNA was reverse transcribed to copy-DNA (cDNA) in a final volume of 40µl containing 400U 
M-MLV reverse transcriptase, 50mM Tris HCl pH 8.3, 75mM KCl, 3mM MgCl2, 10mM DTT,  
1.6nM (dT)15-primer and 0.5mM dNTP for 1 hour at 37°C. To determine the mRNA 
expression of cytokines and their receptors, chemokines, oncogenes and transcription factors, 
real-time PCR was carried out using gene-specific primers in an ABI Prism 7000 sequence 
detection system. PCR reaction was set up with Sybr® Green PCR Master mix containing 
0.3µM primers each and 1µl (7-10ng) of RT-product in 25µl volume. A two-step amplification 
protocol was chosen consisting of initial denaturation at 95 °C for 10 minutes followed by 45 
cycles with 15 seconds denaturation at 95 °C and 30 seconds annealing/extension at 60 °C. 
Finally a dissociation protocol was performed to control specificity of amplification products. 
Relative expression of specific genes was then calculated using the comparative threshold-
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cycle (CT) method. The amount of target mRNA in each sample was set in relation to the 
amount of -actin mRNA designated as calibrator, to give CT (CT gene - CT β-actin). The 
relative expression of gene was calculated as the chemokine/β-actin ratio = 2-∆CT. mRNA gene 
expression is presented as fold change calculated normalized to -actin or 2
-∆∆CT
 values were 
compared in the case of quantification of basal level gene expression in cell lines. 




 cells per dish was homogenized with an Ultra-turrax TP 18/10, three times for 10s each, 
in 10 vol 50 mM TRIS-HCl buffer, pH 7.4, containing 150 mM NaCl, 1 mM EDTA solutions, 
1%Triton X-100, 1 mM phenylmethane sulfonyl-fluoride (PMSF), 1 mM benzamidine, 1 
mg/ml leupeptin, 10 mM chymostatin, 1 mg/ml antipain, and 1 mg/ml pepstatin A. The entire 
procedure was carried out at 4°C. Crude homogenates were passed five times through a 22-G 
needle attached to a syringe and centrifuged for 5 min at 10,000rpm, 4°C. The protein 
concentration was determined in supernatants by using the BCA (bicinchoninic acid) protein 
assay reagent kit (Pierce, Bonn, Germany). Aliquots of the homogenates were stored at −20°C 
until further used for Western blot analysis and measurement. 
3.2.10. Western Blotting 
 
20μg from the total protein lysate were loaded in a 4-12% Nu-PAGE Bis-Tris (Invitrogen) gel 
and separated after 2h electrophoresis at 80V. After the transfer in a semidry apparatus at 30V 
for 1.5h, the membranes were blocked in 5% milk, and blotted with primary antibodies 
overnight at 4°C. The secondary antibodies were horse reddish peroxidase conjugated goat anti-
rabbit and goat anti-mouse immunoglobulins (DAKO) diluted at 1:1000. Membranes were 
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3.2.11.  RNA interference 
 
All the synthetic siRNAs were designed by Qiagen. siRNA transfections were performed in 24-
well plates. Transfection parameters were optimized for each cell line prior to validation 
according to the instructions given in the HiPerFect Transfection Reagent handbook. Optimized 
parameters were 20nM siRNA in combination with (1.5μl, 3μl, 4.5μl) HiPerFect (Qiagen) for 
Caco2 & DLD1 cell lines. Colorectal cells 4x10
4 
(Caco2 & DLD1) were plated in 24-well 
plates prior to transfection the 70% density was monitored. Briefly, for triplicate transfections, 
siRNA and HiPerFect were diluted in 100μl DMEM (Gibco, Grand Island, NY) without serum 
and incubated for 10 min at room temperature. After cell culture medium removal, 500μl fresh 
medium and 100μl transfection complexes were added per well. Cells were incubated for 48h 
and 72h before analyzing the degree of knockdown. Transfection performance was monitored 
using a validated MAPK1 siRNA (MAPK1 control siRNA; Qiagen). RNA isolation RNA 
isolation and purification was performed using the RNeasy protocol (Qiagen), according to the 
manufacturer‟s guidelines. RNA was eluted in 100μl of RNase-free water (Qiagen).  
Generally, at least five independent transfections were carried out per siRNA with three 
replicates each. This procedure was repeated once, resulting in sixteen knockdown values for 
each siRNA. Transfection performance was verified by analyzing the degree of silencing 
obtained with the positive control siRNA (targeting MAPK1) which was transfected in parallel 
on each plate. Plates displaying lower positive control knockdown efficiencies were not 
analyzed. A single PCR was performed for analysis of target and reference gene expression for 
each siRNA transfection. Samples of untransfected cells were analyzed in duplicate for both 
genes. Knockdown values were calculated by the 
-∆
CT method and β-Actin was used as an 
internal standard for normalization. Knockdown values were calculated with reference to 
transfected cells with scrambled siRNA.  
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For Western Blot Analysis 40μg from the total protein lysate were loaded in a 4-12% Nu-
PAGE Bis-Tris (Invitrogen) gel and separated after 2h electrophoresis at 80V. After the transfer 
in a semidry apparatus at 30V for 1.5h, the membranes were blocked in 5% milk, and blotted 
with KRAS primary antibodies overnight at 4°C. The secondary antibodies were horse reddish 
peroxidase conjugated goat anti-rabbit and goat anti-mouse immunoglobulins (DAKO) diluted 
at 1:1000. Membranes were developed with ECL chemiluminescence Kit (Amersham). ß-actin 
was analyzed as an internal control. 
3.2.12. Statistical Analysis 
 
The data were analyzed using Prism Graph pad 5 software (San Diego, USA). All experimental 
errors are shown as SEM. Statistical significance was calculated by Student´s T test and one way 
ANOVA test. Significance was accepted at P < 0.05. 
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4. RESULTS 
4.1 KRAS Mutation in Cell lines 
The known mutations of KRAS were confirmed for the six cell lines (Caco-2, CX-1, Colo-320, 
DLD1, HT-29 and Colo-205). Specific mismatch primers were used to amplify genomic DNA 
fragments through PCR-RFLP assay containing the hot spots of codons G12D and G13D. As 
shown in Figure 10A the positive controls for KRAS G12D and KRAS G13D are identified by 
a band at 134bp whereas the wild type shows a band at 106bp. The detection limit of this assay 
is based on the binding of mismatch primers generating a restriction factor site for BstXI (For 
Codon G12D) and XcmI (For Codon G13D). The amplicons of mutated DNA (Codon 12 & 13) 
were cut only once into fragments of 134 and 18bp, whereas amplicons of wild type DNA were 
cut twice into bands of 106bp, 28bp and 18bp length. The cell line DLD1 showed a band at 
134bp indicating a KRAS G13D mutation (Figure 10B) in comparison to the wild type cell 
lines, which showed a band at 106bp.  The other cell lines Caco2, CX-1, Colo-205 and HT-29 
were found to be wild type after repetitive experiments for the KRAS mutation.  
The KRAS codons A61T and A146V, other hotspots for KRAS mutations, were detected using 
real time PCR. Specific hot spot ARMS primers were designed for the two codons and all the 
six cell lines did not show these KRAS mutations with their respective positive control cell 
lines (Table.5).  
The Ras protein family N-Ras is a small GTPase protein which is normally present in an 
inactive GDP bound form (Dhomen and Marais 2007). These proteins can be activated by 
extracellular signals (e.g. through growth factor receptors) which result in an exchange of GDP 
for GTP (Fearon and Vogelstein 1990a). The hot spot detection via ARMS primer for the N-
Ras mutations G12C and Q61R was performed for the six cell lines and none of the cell line 
was mutated (Table 5).  
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Figure 10:  RFLP PCR electrophoresis for KRAS Codon 12 & 13 mutation analysis for six 
cell lines. The experiment was performed using genomic DNA (10ng) with two restriction 
enzymes BstX1 (Codon G12D) and Xcm1 (Codon G13D) for all the CRC cell lines. (A) Lane 
A: DNA ladder. The lane B and C shows the G12D positive DNA fragment digested either 
with BstX1 (positive control for G12D) or Xcm1 (positive control for G13D). The lane D 
and E shows the G13D positive DNA fragment digested either with BstX1 (positive control 
for G12D) or Xcm1 (positive control for G13D). Lane F and G shows the wild type DNA 
fragment digested either with BstX1 (positive control for G12D) or Xcm1 (positive control 
for G13D). Positivity resulted in a band at 134bp (fragment cut only at control cleavage 
site). (B) Colorectal Cell lines: Lane A; DNA Ladder; Lanes B-M fragments obtained after 
PCR and digestion with either BstX1 or Xcm1. Lane E confirms G13D mutation in the 
DLD1 cell line at base pair 134. 
4.2 BRAF Mutation in Cell lines 
BRAF is a serine/threonine kinase that belongs to the RAS/RAF/MEK/ERK/MAPK pathway, 
which is involved in the transduction of mitogenic signals from the cell membrane to the 
nucleus. RAS is inactive when bound to GDP, but if activated it promotes phosphorylation and 
activation of BRAF and further activation of the pathway signal (Davies et al. 2002a). 
Genomic DNA (10ng) extracted from the human CRC cell lines was amplified as described in 
the methods. Two allele-specific amplicons were generated using two pairs of primers, one pair 
producing an amplicon representing the A (mutated) allele and the other T (wild type) allele. 
The x-axis in the (Fig.11), representing the ∆Rn (normalized reporter) which is obtained after 
the normalization of Rn by subtracting the baseline. The x-axis (Fig. 11) shows the CT values 
the fractional cycle number at which the fluorescence passes the threshold. In a real time PCR 
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assay a positive reaction is detected by accumulation of a fluorescent signal. The Ct (cycle 
threshold) is defined as the number of cycles required for the fluorescent signal to cross the 
threshold (i.e exceeds background level). Ct levels are inversely proportional to the amount of 
target nucleic acid in the sample (i.e the lower the Ct level the greater the amount of target 
nucleic acid in the sample). The genotyping primer mix contains two labeled probes 
homologous to the two genotypes (A or T). During real-time PCR amplification of the target 
DNA, the probes will compete for binding across the variant region. The probe that is 100% 
homologous to the DNA binding site will preferentially bind and give a fluorescent signal as 
PCR proceeds. It follows that the wild type sequence will give a strong amplification plot 
through one channel whilst giving a very weak signal through the alternative channel. 
Homozygous variant samples will give an exactly inverse result. Heterozygous samples contain 
both probes binding sites on each of the two alleles and therefore give an intermediate signal 
through both channels.         
All the cell lines were tested for the Braf mutations. Braf mutation (heterozygote) at hotspot 
V600E was confirmed in the two cell lines HT-29 and Colo-205 (Table.5). The other four cell 
lines were wild type for the Braf mutation. 
 
Figure 11: Real Time® PCR assays for BRAF V600E mutation detection. (Fig11A.) The plot 
confirms the heterozygotic mutant allele in HT-29 cell line. (B) Negative control cell line 
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that indicates the primer A and T for the wild type cell lines at distant position resembles 
the wild type.   
Table5: List of Mutations of KRAS, NRAS and BRAF for different hotspots  
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Table6: List of Mutations for different hotspots in six colorectal cell lines.  
 
 
Source:  Atlas of Genetics and Cytogenetics (www.sanger.ac.uk) 
   The Roche Cancer Genome Database (www.rcgdb.bioinf.uni-sb.de) 
 
4.3 Basal changes in mRNA expression of acute phase cytokines in Intestinal 
 Epithelial Cell lines (IECs) 
 
The gene expression of major cytokines (TNFα, IL-1ß and IFNγ) was studied at basal level in 
five CRC cell lines. We excluded the CX-1 (non-adherent) cell line in the following 
experiments and continued with two wild type cell lines i.e Caco2 and Colo-320. Previously, it 
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has been published that IECs depending on their origin and maturity may have a different and 
distinct pattern of chemokine/cytokine expression (Yang et al. 1997).   Using gene specific 
primers the real time PCR data showed that the basal mRNA expression of TNFα normalised to 
ß-actin expression was highest in Caco2 (Wt) followed by HT-29 (BRAF) and the lowest 
expression was observed in the DLD1(KRAS) cell line (Figure 12A; p<0.05). The highest IL-
1ß expression was observed in both the BRAF mutated cell lines HT-29 and Colo-205, 
followed by the two wild type Colo-320 and Caco2 respectively. The lowest expression for IL-
1ß was found in DLD1 (KRAS) (Figure 12B; p<0.05). The overall analysis of the basal level 
indicates that expression was very low in the KRAS mutated cell line DLD1 for the pro-
inflammatory cytokines (TNFα and IL-1ß). Moreover, IFNγ and IL-6 have shown no 
expression for any of the cell lines in the experiment (Figure 12C& D).       
 
Figure 12: Basal mRNA expression of acute-phase cytokines (TNF-α, IL1-β & IFNγ) in 
Intestinal Epithelial Cells. 5 105 cells were plated into 6 well plates and grown for 24 hours. 
The cells were harvested, total RNA was isolated and first strand cDNA was prepared from 
1 µg of total RNA. Ct values were normalized to ß-actin as a housekeeping gene. The results 
were compared with the fold changes of Caco2 mRNA expression, taken as a control. 
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4.4 Basal changes in mRNA expression of acute phase cytokines receptors in 
 Intestinal Epithelial Cell lines (IECs) 
 
The basal level of cytokine receptor mRNA expression in the five cell lines revealed, that Colo-
205 and HT-29 (BRAF mutated) have shown the highest expression for TNFα Rec1 (Figure 
13A; p<0.05). IL-1ß Rec was found in Caco2 (Wt) followed by DLD1 (KRAS) and Colo-205 
(Braf) (Figure 13B; p<0.05). Even though IFNγ did not show any expression for the five cell 
lines at the basal level, IFNγ Rec1 has shown a relatively high mRNA expression for the cell 
lines, also in comparison with TNFα Rec1 and IL-1ß Rec 1. IFNγ Rec1 resulted in maximum 
expression for the Colo-205 and HT-29 (BRAF) followed by Caco2 (Wt) (Figure 13C; 
p<0.05).  
 
Figure 13: Basal mRNA expression of cytokine receptors (TNF-α Rec1, IL1-β and IFNγ 
Rec1) in IECs. 5 105 cells were plated into 6 well plates and grown for 24 hours. The cells 
were harvested, total RNA was isolated and first strand cDNA was prepared from 1 µg of 
total RNA. Ct values were normalized with ß-actin as a housekeeping gene. The results 
were compared with the fold changes of Caco2 mRNA expression, taken as a control. 
Results represent mean value ± S.E.M. (*p ≤0.05, **p ≤0.01 analyzed by one way ANOVA, 
n=4).  
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4.5 Differential Basal mRNA expression of pro inflammatory chemokines 
 (CXCL1, CXCL8 and CXCL10) in Colorectal Cell lines (CRC) 
The differences in the basal level of mRNA expression of chemokines were studied in five 
different cell lines. The mRNA expression of CXCL1 and CXCL8 was significantly higher in 
the mutated cell lines HT-29 (Braf) followed by Colo-205 (BRAF) and DLD1 (KRAS) (Figure 
14A&B; p<0.05). However, the expression was low in the wild type cell lines Caco2 and Colo-
320. In contrast CXCL10 mRNA was significantly increased in the wild type cell lines Caco2 
and Colo-320. It was found that CXCL10 mRNA expression was lowest in the mutated cell 
lines (HT-29, DLD1 and Colo-205) (Figure 14C; p<0.05).  
 
Figure 14: Basal mRNA expression of chemokines (CXCL1, CXCL8, and CXCL10) in IECs. 
5 105 cells were plated into 6 well plates and grown for 24 hours. The cells were harvested, 
total RNA was isolated and first strand cDNA was prepared from 1 µg of total RNA. Ct 
values were normalized with ß-actin as a housekeeping gene. The results were compared 
with the fold changes of Caco2 mRNA expression, taken as a control. Results represent 
mean value ± S.E.M. (*p ≤0.05, **p ≤0.01 analyzed by one way ANOVA, n=4).  
 
4.6 Selection of cell lines for the cytokine stimulation. 
 
Three cell lines were chosen for the cytokine stimulation; Caco2 (Wt), DLD1 (KRAS) and HT-
29 (BRAF). As a focus of our study was to investigate the cytokine / chemokine profile in view 
of the KRAS and BRAF mutations of the CRC cell lines, the three above stated cell-lines were 
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selected. Caco2 is wild type for KRAS and BRAF and therefore served as control. It has a high 
basal mRNA expression level for the TNFα, TNFα Rec1, IL-1ß Rec1, and IFNγ Rec1 by 
comparison to CX-1and colo-320. HT-29 (BRAF) was selected instead of Colo-205 (BRAF) 
because of its highly mutational status, growth properties (adherent) and its basal mRNA 
expression for TNFα and IL-1ß. DLD1 selection was based on its mutational status of KRAS 
codon G13D (Table.6). 
The two cell lines CX-1 and Colo-320 have other mutations in the APC (both) and TP-53 
(colo-320) gene (Table.6).  
4.7 Changes in the mRNA expression of CXCL1 in colorectal cancer cell lines 
Caco2 (Wt), DLD1 (KRAS) and HT-29 (BRAF) by cytokines (TNFα, IL-1ß and 
IFNγ). 
 
4.7.1 Regulation of CXCL1 mRNA expression by cytokines. 
 
Three cell lines with two different mutations DLD1 (KRAS), HT-29 (BRAF) and Caco-2 (Wild 
type) were examined for the time kinetics of CXCL1 mRNA expression and protein secretion. 
The cytokines were administered at the following concentrations: IL-1  [1ng/ml], TNF  
[50ng/ml] and IFN  [50ng/ml] were administered to IECs.  
Under control conditions CXCL1 mRNA expression did not change over the time. CXCL1 
mRNA was inducible early at 1h after stimulation with TNF  in DLD1 (KRAS), 
(310±2.18fold) followed by HT-29 (BRAF; 36.15±3.28fold) whereas no change was detected 
in CXCL1 mRNA expression in the Caco2 cell line. The induction by TNFα of CXCL1 in HT-
29 was milder as compared to DLD1 but lasted until 8h after stimulation, while in DLD1 it 
lasted only until 2h at high levels (Figure 15B; p<0.05). IL-1ß induced gene expression of 
CXCL1 in HT-29 (BRAF; 46.42±5.98 fold) was highest, followed by DLD1 (KRAS; 
21.19±0.37fold) however, in Caco2 (Wt) IL-1ß did not effect the CXCL1 gene expression 
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(Figure 15C; p<0.05).  IFNγ stimulation showed a delayed increase of CXCL1 gene 
expression in Caco2 (Wt; 346.84±23.01fold) which was highest at 24h, followed by HT-29 
(BRAF; 14.43+.50fold) at 8h (Figure 15D; p<0.05). 
 
Figure 15: (A, B, C, and D). Regulation of CXCL1 mRNA expression by cytokine in 
Intestinal Epithelial Cells. 5 105 cells were plated into 6 well plates and grown for 24 
hours and then stimulated with TNFα (50ng), IL-1ß (1ng), and IFNγ (50ng). The cells were 
harvested, total RNA was isolated and first strand cDNA was prepared from 1 µg of total 
RNA. Ct values were normalized with ß-actin as a housekeeping gene. Results represent 
mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed by one way ANOVA, n=3).   
 
4.7.2 Changes in the protein expression of CXCL1 in colorectal cancer cell lines 
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The effect of cytokine stimulation on CXCL1 was further analysed at protein level by Western 
blot (Figure 16A, B & C) in Caco-2 (Wt), DLD1 (KRAS) and HT-29 (BRAF) cell lines. 
Western blot analysis was performed by using anti-CXCL1 antibody to confirm the changes 
occurring at mRNA level and to document the protein expression of CXCL1 chemokine in 
IECs over the time.  
TNF-α stimulation 
The CXCL1 protein secretion under control conditions did not vary to a greater extent in the 
analysed cell lines. Similar to what was observed at mRNA level, DLD1 showed a significant 
and early increase at 1h (1126±130-percent) and a maximum at 2h (1236±151-percent) after 
TNFα stimulation compared to the baseline conditions.  In contrary to mRNA level, an increase 
in CXCL1 was detected with a maximum at 8h (847±180-percent) in the Caco2 cell line in 
comparison to their controls. The HT-29 cell line showed an increase at 2h and 8h followed by 
decrease at 24h as compared to respective controls. The data demonstrates that TNFα at protein 
level also showed significant increase in KRAS mutated cell line (DLD1).  
IL-1ß stimulation 
Similar to the mRNA expression, IL-1ß induced a significant protein level of CXCL1 in all the 
studied cell lines. Among them, an increase in Caco2 was the most pronounced at 2h (837±108-
percent) and 8h (827±160-percent) compared to untreated cells. However, a statistically 
significant expression was detected in all studied time points as was also observed for HT-29 
and DLD1 after IL-1ß stimulation. 
IFNγ stimulation  
Likewise regarding mRNA expression, a clear gradual increase for CXCL1 in Caco2 was 
observed after IFNγ stimulation. This increase was at its maximum by 8h (1371±293-percent) 
in Caco2.  HT-29 (BRAF) and DLD1 (KRAS) also showed an increase with a maximum at 2h 
after IFNγ stimulation. (Figure 16A, B&C). 
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Taken together, a significant increased protein level of CXCL1 was observed by treatment of 
cytokines (TNF-α, IL1-β & IFNγ) in all studied cell lines [(Caco-2(Wt), DLD1(KRAS) and 
HT-29 (BRAF)]. However, we could observe a difference among some cytokines treatments 
and cell lines between the mRNA and protein expression. It might be due to the secretory 
nature of proteins which makes it difficult to compare CXCL1 protein expression to mRNA 
expression in mutated and wild type cell lines, as the proteins might be released into the 
supernatant. 
 
Figure 16: (A, B, C) shows Caco-2(Wt), DLD1(KRAS) and HT-29 (BRAF) western blot 
analysis. The cytokines IL-1  (1ng/ml), TNF  (50ng/ml) and IFN  (50ng/ml) were 
stimulated to the cells and the total cell lysates was isolated and 20 g were separated by 15-
20% NuPAGE Bis-Tris gel electrophoresis, blotted and probed with CXCL1 antibody. ß-
Actin (43Kda) was analyzed as an internal control. Figure16 (D, E, F) represents the 
desitometric analysis of western blots of three independent experiments of CXCL1 (11kDa). 
The graphs shows percentage changes of protein amount in comparison with their 
respective controls. Densitometry was performed using Image J software. Results represent 
mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed by one way ANOVA, n=3).   
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4.8  Changes in the mRNA expression of CXCL8 in colorectal cancer cell lines 
 Caco2 (Wt), DLD1 (KRAS) and HT-29 (BRAF) by cytokines (TNFα, IL-1ß 
 and IFNγ). 
4.8.1  Regulation of CXCL8 mRNA expression by cytokines. 
 
Due to its chemo-attractive function, CXCL8 is also known to increase angiogenesis in many 
carcinomas (Fujimoto et al. 2002;Inoue et al. 2000;Smith et al. 1994;Yoneda et al. 1998). The 
CXCL8 mRNA gene expression showed that no induction was observed under control 
conditions in all three cell lines (Figure 17A, p<0.05). In accordance to mRNA data, TNFα 
stimulation strongly induced CXCL8 in the mutated cell lines compared to control. A strong 
and constant up-regulation was observed in HT-29 (BRAF; 165+30.33fold) after TNFα 
treatment that persists until 24h. Accordingly, the maximum expression after TNFα stimulation 
at 1h in DLD1(KRAS; 80.31+4.77fold) and Caco-2(Wt; 45.43+1.43fold) was increased 
(Figure 17B; p<0.05). IL-1ß treatment showed significant up-regulation of CXCL8 with a 
maximum expression by 1h in Caco2 (Wt; 806.41±19.76 fold) followed by DLD1 (KRAS; 
353.22±40.63 fold) and HT-29 (BRAF; 41.51±0.72 fold) (Figure 17C; p<0.05). IFN  was 
ineffective in inducing the CXCL8 expression at early time, however, a mild and late increase 
was observed in HT-29 (BRAF; 5.70±1.18) fold (Figure 17D; p<0.05). 
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Figure 17: (A, B, C, and D) Time Kinetics of CXCL8 mRNA expression in Intestinal 
Epithelial Cells. 5 105 cells were plated into 6 well plates and grown for 24 hours and then 
stimulated with TNFα (50ng), IL-1ß (1ng), and IFNγ (50ng). The cells were harvested, total 
RNA was isolated and first strand cDNA was prepared from 1 µg of total RNA. Ct values 
were normalized with ß-actin as a housekeeping gene. Results represent mean value ± 
S.E.M. (*p≤0.05, **p≤0.01 analyzed by one way ANOVA, n=3).   
 
4.8.2 Changes in the Protein expression of CXCL8 in colorectal cancer cell lines 
 Caco2 (Wt), DLD1 (KRAS) and HT-29 (BRAF) by cytokines (TNFα, IL-1ß 
 and IFNγ). 
 
Western blot analysis was performed for the protein CXCL8 (11Kda) in Caco-2 (Wt), DLD1 
(KRAS) and HT-29 (BRAF). Similar to mRNA expression under control condition, there were 
no significant changes observed at protein level.  
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After TNF  stimulation, the quantification of CXCL8 protein expression indicated an early 
gradual increase in DLD1 that lasts till 24h (1240±300-percent). Caco2 also showed an increase 
at 4h (843±97-percent) and 8h (828±107-percent) respectively. HT-29 showed a gradual mild 
increase due to TNF  stimulation at protein level in comparison with other two cell lines 
(Figure 18D). 
IL-1  stimulation revealed an early increase at 1h in DLD1 and this increase had its maximum 
at 8h (1020±326-percent). A mild but significant increase in Caco-2 was also revealed due to 
the IL-1ß stimulation that lasts until 24h, however the changes in HT-29 were non-significant 
compared to the untreated controls (Figure 18E).  
As was observed in DLD1, IFNγ stimulation, showed an early increase of CXCL8 with a 
maximum at 4h (1189±211-percent) which persisted until 24h (unlike for mRNA expression),  
whereas Caco2 and HT-29 showed a mild increase at protein level compared to controls 
(Figure 18F).  
Taken together, at protein level CXCL8 data demonstrated that due to cytokines stimulation the 
KRAS mutated cell line DLD1 showed the most prominent and continuous changes compared 
to the other cell lines.   
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Figure 18: (A, B, C) shows Caco-2(Wt), DLD1(KRAS) and HT-29 (BRAF) western blot 
analysis. The cytokines IL-1  (1ng/ml), TNF  (50ng/ml) and IFN  (50ng/ml) were 
stimulated to the cells and the total cell lysates was isolated and 20 g were separated by 15-
20% NuPAGE Bis-Tris gel electrophoresis, blotted and probed with CXCL8 antibody. ß-
actin (43Kda) was analyzed as an internal control. Figure18 (D, E, F) represents the 
desitometric analysis of western blots of three independent experiments of CXCL8 (11kDa). 
The graphs shows percentage changes of protein amount in comparison with their 
respective controls. Densitometry was performed using Image J software. Results represent 
mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed by one way ANOVA, n=3).   
4.9 Changes in the mRNA expression of CXCL10 in colorectal cancer cell 
lines Caco2 (Wt), DLD1 (KRAS) and HT-29 (BRAF) by cytokines (TNFα, IL- 1ß 
and IFNγ). 
 
4.9.1  Regulation of CXCL10 mRNA expression by cytokines. 
 
CXCL10 has shown different expression after cytokine stimulation in each cell line. The 
mRNA expression under control conditions showed no difference in the cell lines. TNFα 
induced the maximum CXCL10 gene expression in HT-29 (BRAF; 163.14 0.1fold) after 8h. 
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However, in DLD1 (KRAS) and Caco2 (Wt) cell lines a low CXCL10 mRNA expression was 
observed (Figure 19B; p<0.05).  
IL-1ß treatment showed a maximum CXCL10 gene expression in HT-29 (BRAF) 
(49.72 6.25fold) followed by Caco2 (Wt) (36.86 5.13fold) with a maximum expression after 
2h, whereas DLD1 showed mild changes compared to non-stimulated controls (Figure 19C; 
p<0.05).  
In our experiment IFNγ significantly enhanced CXCL10 mRNA expression in mutated cell 
lines HT-29 (BRAF; 15361.19±2974.33fold) followed by DLD1 (KRAS; 597.71±64.62 fold) in 
contrast to the wild type cell line Caco2 (Wt; 45.75±1.44fold) (Figure 19D; p<0.05).   
  
 




Figure 19: (A, B, C, and D) Time Kinetics of CXCL10 mRNA expression in IECs. 5 105 cells 
were plated into 6 well plates and grown for 24 hours and then stimulated with TNFα 
(50ng), IL-1ß (1ng), and IFNγ (50ng). The cells were harvested, total RNA was isolated and 
first strand cDNA was prepared from 1 µg of total RNA. Ct values were normalized with ß-
Actin as a housekeeping gene. Results represent mean value ± S.E.M. (*p≤0.05, **p≤0.01 
analyzed by one way ANOVA, n=3).   
 
4.9.2 Changes in the Protein expression of CXCL10 in colorectal cancer cell 
  lines Caco2 (Wt), DLD1 (KRAS) and HT-29 (BRAF) by cytokines (TNFα, IL-
 1ß and IFNγ). 
 
The Western blot analysis of CXCL10 revealed weak expression for all the cell lines under 
control conditions.  
TNFα stimulation showed no significant changes in any of the three cell lines.  
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HT-29 showed a highly significant increase due to IL-1ß after one hour and reaching at its 
maximum by 24h (1525±125-percent). 
Also IFNγ stimulation increased CXCL10 expression in HT-29 at early 1h (1358±81-percent) 
and the same expression was found throughout the study (Figure 20 D, E, F). 
 
Figure 20: (A, B, C) shows Caco-2(Wt), DLD1(KRAS) and HT-29 (BRAF) western blot 
analysis. The cytokines IL-1  (1ng/ml), TNF  (50ng/ml) and IFN  (50ng/ml) were 
stimulated to the cells and the total cell lysates was isolated and 20 g were separated by 15-
20% NuPAGE Bis-Tris gel electrophoresis, blotted and probed with CXCL10 antibody. ß-
actin (43Kda) was analyzed as an internal control. Figure 20 (D, E, F) represents the 
densitometric analysis of western blots of three independent experiments of CXCL10 
(11kDa). The graphs shows percentage changes of protein amount in comparison with their 
respective controls. Densitometry was performed using Image J software. Results represent 
mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed by one way ANOVA, n=3).   
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4.10 Transcription Factors Mitogen Activated Protein Kinases (MAPK1), 
 Nuclear Factor of kappa B (NFκB) and Signal Transducer and Activator of 
 Transcription (STAT3) Phosphorylation at base level in Intestinal 
 Epithelial Cells (IECs). 
 
4.10.1  Basal mRNA expression of MAPK1 in DLD1 and Caco2: 
 
Mitogen-activated protein kinases (MAPKs) play a pivotal role in the mitogenic signal 
transduction pathway and are essential components of the MAPK cascade, which includes 
MEK (also known as MAP kinase), Raf-1, and Ras (Oka et al. 1995). In this study, we 
examined whether constitutive activation of the MAPK cascade was associated with the 
carcinogenesis of human colorectal carcinomas compared to controls.The basal mRNA 
expression was studied first. The gene specific primers for MAPK1 revealed that the basal 
mRNA expression was higher in DLD1(KRAS) compared to Caco2 (Wt) (Figure 21A; 
p<0.05). 
4.10.2  Basal mRNA expression of NF-κB in DLD1 and Caco2: 
 
To evaluate the possible role of NF-κB in cytokine induced chemokine gene expression and 
transcription factors detected against the activated proteins in the intestinal epithelial cell lines, 
experiments with a gene specific NF-κB primer were performed. Most tumor-promoting 
cytokines are activated via NF-κB or activate NF-κB signalling in pre-malignant cells and 
immune/inflammatory cells (Karin 2006). The basal mRNA expression was studied in the two 
colorectal cell lines. The gene specific primers for NF-κB revealed that the basal mRNA 
expression of NF-κB was highest in DLD1(KRAS) in comparison with Caco2 (Wt) (Figure 
21B; p<0.05). 
4.10.3  Basal mRNA expression of STAT3 in DLD1 and Caco2: 
 
STAT3 basal mRNA expression was analyzed for the two colorectal cell lines. STAT3 is 
frequently activated in many types of human solid and blood cancers and contributes to 
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progression of those cancers (Buettner et al. 2002;Turkson and Jove 2000). The STAT3 
pathway is also frequently constitutively activated in CRC and is considered to play an 
important role in colorectal carcinogenesis (Corvinus et al. 2005;Kusaba et al. 2005;Lin et al. 
2005;Ma et al. 2004;Tsareva et al. 2007;Xiong et al. 2008). To study the effect of the STAT3 
pathway in IECs, we performed real time-PCR for the two colorectal cancer cell lines by using 
the gene specific oligo-nucleotides. The basal mRNA expression of STAT3 in two different 
cell lines (Caco2 and DLD1) revealed that a mild increase of STAT-3 in the mutated cell line 
DLD1 (KRAS) compared to Caco2 (Figure 21C; p<0.05).    
 
 
Figure 21: (A). Basal mRNA expression Transcriptional factor MAPK1. (B). Basal mRNA 
expression Transcriptional factor NF-κB. (C). Basal mRNA expression Transcriptional factor 
STAT-3. 5 105 cells were plated into 6 well plates and grown for 24 hours. Ct values were 
normalized with ß-actin as a housekeeping gene. The results were compared with the 
Caco2 taken as a control. Results represent mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed 
by one way ANOVA, n=4).  
 
4.11 Changes in the Protein expression of MAPK1 in colorectal cancer cell 
 lines Caco2 (Wt) and DLD1 (KRAS) by cytokines (TNFα, IL-1ß and IFNγ). 
 
Western blot analysis was performed to demonstrate the changes in p-MAPK1 protein 
expression in Caco2 (Wt) and DLD1 (KRAS) cell lines. It was possible to detect the p-MAPK1 
protein in both cell lines by using antibody against p-MAPK1 without any stimulation 
(controls).  An increased protein level of the p-MAPK1 was observed after different cytokine 
 
 59  
 
stimulation. A significant increase in p-MAPK1 at protein level was detected with a maximum 
at 8h (541.04±101.17-percent) after TNFα stimulation in the DLD1 cell line. A similar pattern 
was also seen in Caco2 with a maximum expression at 8h (448.57±32.20-percent) (Figure 
22C). Similarly, IL-1ß stimulation also showed an increase of p-MAPK1 protein expression in 
DLD1 and Caco2 cell lines. The desitometric analysis of DLD1 showed a maximum increase at 
24h (898±252-percent) after IL-1ß stimulation as compared to Caco2 (Figure 22D). IFNγ 
stimulation showed continuous increase at p-MAPK1 protein level expression in DLD1 
(KRAS) and a maximum increase was detected at 24h (1230±158-percent) as compared to 
Caco2 cell line (Figure 22E). Taken together, the DLD1 (KRAS) cell line showed a higher 
MAPK1 induction after cytokines stimulation compared to Caco-2 (Wt).  
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Figure 22: (A, B) shows Caco-2(Wt) and DLD1(KRAS) western blot analysis. The cytokines 
IL-1  (1ng/ml), TNF  (50ng/ml) and IFN  (50ng/ml) were stimulated to the cells and the 
total cell lysates was isolated and 20 g were separated by 15-20% NuPAGE Bis-Tris gel 
electrophoresis, blotted and probed with MAPK1 antibody. ß-actin (43Kda) was analyzed 
as an internal control.  
Figure 22 (C, D, E) represents the desitometric analysis of western blots of three 
independent experiments of MAPK1 (44kDa). The graphs shows percentage changes of 
protein amount in comparison with their respective controls. Densitometry was performed 
using Image J software. Results represent mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed 
by one way ANOVA, n=3).   
 
4.12 Changes in the Protein expression of NF-κB in colorectal cancer cell lines 
 Caco2 (Wt) and DLD1 (KRAS) by cytokines (TNFα, IL-1ß and IFNγ). 
By using antibody against NF-κB in Western blot, it was possible to detect the NF-κB protein 
in both cell lines without any stimulation (controls).  A dramatic increase was detected in 
protein level of NF-κB in both DLD1 and Caco-2 after different cytokine stimulation. After 
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TNFα stimulation, a significant increase in NF-κB at protein level was detected with a 
maximum at 8h (658±16.01-percent) in the Caco2 cell line. A similar pattern was also seen in 
DLD1 with a maximum expression at 4h (415.77±42.75-percent) (Figure 23C). Likewise, IL-
1ß stimulation also showed an increase of NF-κB protein expression in Caco2 and DLD1cell 
lines.  
After IL-1ß stimulation, the Western blot analysis of Caco2 showed a maximum increase at 2h 
(782±46-percent) as compared to DLD1 (Figure 23D).  
IFNγ treatment showed an increase in NF-κB protein level expression in Caco2 (Wt) cell line, 
and a maximum increase was detected at 2h (1179±157.25-percent) as compared to DLD1 
(KRAS) cell line (Figure 23E).  
The desitometric analysis showed an increase at protein level by the treatments (TNFα, IL1ß 
and IFNγ) stimulation in the Caco2 and DLD1 cell line throughout the experiment (Figure 
23C, D & E; p<0.05). These data suggest that Caco-2 (Wt) cell line showed a higher NF-κB 
induction after cytokine stimulation compared to DLD1 (KRAS) cell line. 
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Figure 23: (A, B) shows Caco-2(Wt) and DLD1(KRAS) western blot analysis. The cytokines 
IL-1  (1ng/ml), TNF  (50ng/ml) and IFN  (50ng/ml) were stimulated to the cells and the 
total cell lysates was isolated and 20 g were separated by 15-20% NuPAGE Bis-Tris gel 
electrophoresis, blotted and probed with IκBα antibody. ß-actin (43Kda) was analyzed as 
an internal control. Figure 23 (C, D, E) represents the densitometric analysis of western 
blots of three independent experiments of NFκB (65kDa). The graphs shows percentage 
changes of protein amount in comparison with their respective controls. Densitometry was 
performed using Image J software. Results represent mean value ± S.E.M. (*p≤0.05, **p≤0.01 
analyzed by one way ANOVA, n=3).   
 
4.13 Changes in the Protein expression of p-STAT3 in colorectal cancer cell 
 lines Caco2 (Wt) and DLD1 (KRAS) by cytokines (TNFα, IL-1ß and IFNγ). 
Western blot analysis was performed to demonstrate the changes in p-STAT3 protein 
expression in Caco2 (Wt) and DLD1 (KRAS) cell lines after treatment with inflammatory 
cytokines. It was not possible to detect a basal protein expression for the p-STAT3 in Caco2 
and DLD1 cell lines. Western blot analysis showed fully diminished expression in the cell lines 
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under control conditions. However, our Western blot results revealed a strong induction of p-
STAT3 after IFNγ stimulation in the DLD1 cell line.  The p-STAT3 started to increase at 1h 
(1304±389.19-percent) and a pronounced increase was measured at 4h (2597±350 percent) 
which lasted till 24h (739±199percent) (Figure 24B & E).  
Taken together, it clearly indicates the possible role of p-STAT3 after IFNγ stimulation in 
KRAS mutated cell line (DLD1). In contrast, TNFα and IL-1ß showed no detection of p-
STAT3 in DLD1. Similarly, no visible band was observed in Caco2 by treatment of any 
cytokines (Figure 24A,C & D).  
 
Figure 24: (A) (B) Shows Caco-2(Wt) and DLD1(KRAS) western blot analysis. The 
cytokines IL-1  (1ng/ml), TNF  (50ng/ml) and IFN  (50ng/ml) were stimulated to the cells 
and the total cell lysates was isolated and 20 g were separated by 15-20% NuPAGE Bis-Tris 
gel electrophoresis, blotted and probed with p-STAT3 antibody. ß-actin (43Kda) was 
analyzed as an internal control. (C) (D) and (E) represents the desitometric analysis of 
western blots of three independent experiments of p-STAT3 (80kDa) in DLD1 cell lines. 
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The graphs shows percentage changes of protein amount in comparison with their 
respective controls. Densitometry was performed using Image J software. Results represent 
mean value ± S.E.M. (*p≤0.05, **p≤0.01 analyzed by one way ANOVA, n=3).   
 
4.14  Knockdown of KRAS Expression in DLD1(KRAS) and Caco-2(Wt).  
 
4.14.1 KRAS knockdown mRNA and protein expression in DLD1 and Caco2: 
 
For down-regulation of KRAS expression in DLD1 (KRAS) and Caco-2 (Wt) cells, KRAS-
specific siRNA (Qiagen) was used in transfection studies. Two human colorectal carcinoma 
cell lines DLD1 and Caco2 were chosen to examine the different effects of KRAS knockdown 
in a wild type compared to a KRAS mutated cell line. We tried to keep the siRNA 
concentration as low as possible for each cell line, and performed several experimental 
combinations of siRNA transfection (Table.7). All experiments were carried out with high 
perfect reagent according to the Qiagen protocol. The initial experiments were started with 
1nM siRNA and 2μM (1.5μl) high perfect reagent. The experiments were performed in three 
replicates for both cell lines. Knockdown of KRAS was determined by real time PCR and at 
protein level through Western blot.  Finally 5x10
4
 cells were plated in 24 wells with a 
concentration of 20nM siRNA (6μl) and 10nM High perfect (12μl) which was considered to be 
a combination which resulted in an acceptable KRAS knock down after 48h and 72h incubation 
time for the following experiments (Figure 25 A, B). Scrambled siRNA was taken as a control.  
Table7: Different conditions tested to achieve optimal siRNA knock down.  
 
In both cell lines, DLD1 and Caco2, the total KRAS knockdown expression was studied after 
48h and 72h and compared to the scrambled siRNA. To quantitatively determine the down 
regulation of KRAS expression, both the cell lines were measured by Real Time PCR at mRNA 
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level. The results revealed that siRNAs down-regulated KRAS mRNA expression after 48h in 
DLD1 (25%) and Caco2 (20%), respectively. Whereas after 72h incubation siRNA 
significantly reduced KRAS mRNA expression to approximately DLD1 (55%) and Caco2 
(58%), respectively (Figure 25A&B; p<0.05).  
However, at protein level the results showed a striking difference as compared to mRNA 
results. By using antibody against KRAS, Western blots analysis of three independent 
experiments revealed a significant reduction in KRAS protein expression in DLD1 cell line. 
The most pronounced inhibition was observed at 48h (67% KRAS knockdown) and 72h (85% 
KRAS knockdown) after siRNA transfection. 
Similar results were also detected in the Caco2 cell line with a maximum at 48h (67% KRAS 
knockdown) and after 72h (62% KRAS knockdown) after KRAS transient transfection (Figure 
25C,D,E&F; p<0.05).  
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Figure 25:  (A&B) Shows transient Transfection of KRAS siRNA in DLD1 and Caco2 Cell 
lines at mRNA level. The data is the representation of three independent experiments. 
(C&D) are the representatives of KRAS siRNA knockdown western blot analysis. (E&F) 
protein bands of three independent experiments were densitometrically quantified. The 
relative bands indicated as percent change compared with scrambled siRNA in DLD1 and 
Caco2 cell lines.   5 104 cells were plated into 24 well plates and grown for 24 hours and 
then transfected with KRAS siRNA or scrambled (20nM) for 48h and 72h. Real Time PCR 
was performed for KRAS with gene specific primers and the expression was normalized to 
-actin expression measured in the same sample as an internal control. For western blot cell 
lysates were size fractionated by SDS-PAGE, blotted and analyzed with antibodies specific 
for KRAS. ß-actin specific antibody to check for equal loading of total protein. Data 
presented are the means ± SEM of 3 independent experiments with double confirmation. * 
corresponds to p  0.05. 
4.14.2 Changes in chemokines mRNA expression due to KRAS knockdown in 
 DLD1 and Caco2. 
 
To further explore the consequences of decreased KRAS expression in the cell lines due to 
KRAS siRNA knockdown, we studied the chemokines gene expression at mRNA level.  
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A significant decrease in CXCL1 mRNA level was detected after 72h (0.31 0.07 fold; p<0.05 
vs. scrambled control) transfection in the DLD1 cell line. Similarly CXCL10 also showed a 
decrease (0.30 0.08fold; p<0.05 vs. scrambled control) gene expression after 72h transfection 
due to KRAS inhibition. In contrast, CXCL8 (0.66 0.23fold; p<0.05 vs. scrambled control) 
mRNA expression was up-regulated in DLD1 after KRAS knockdown in comparison with its 
scrambled control (Figure 26A, B&C; p<0.05). 
On the contrary to DLD1 (KRAS), in Caco2 (Wt) cell line, the KRAS knockdown resulted in 
up-regulation of CXCL1 (9.79 3.6fold; p<0.05 vs. Scrambled Control), CXCL8 mRNA 
(1.71 0.05fold; p<0.05 vs. Scrambled Control) and CXCL10 (18.40 12.80fold; p<0.05 vs. 
Scrambled Control) mRNA expression after 72h transfection (Figure 26D, E &F; p<0.05). 
To summarize, the results indicate a change in cytokine-gene expression of both cell lines after 
KRAS inhibition. Moreover, CXCL1 and CXCL10 showed an opposite expression in the two 
cell lines, whereas gene expression of CXCL8 was induced in both cell lines by KRAS 
knockdown. 
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Figure 26:  Transient Transfection of KRAS siRNA in DLD1 (KRAS) and Caco-2(Wt) Cell 
line. 5 104 cells were plated into 24 well plates and grown for 24 hours and then 
transfected with Kras siRNA or scrambled (20nM) for 72h. Real Time PCR was performed 
for CXCL1, CXCL8 and CXCL10 with gene specific primers and the expression was 
normalized to -actin expression measured in the same sample as an internal control. Data 
presented are the means ± SEM of 4 independent experiments with double confirmation. * 
corresponds to p  0.05. 
4.14.3 Changes in protein expression of MAPK1and IκBα due to KRAS 
 knockdown in DLD1 (KRAS) and Caco2. 
 
To further evaluate the reason of change in chemokine gene expression by KRAS-knock down 
in both DLD1 and Caco2 cell lines, transcription factors MAPK1 and IκBα were analysed at 
protein level.  MAPK1 specific protein band was detectable at 44kDa in DLD1 and Caco-2 
cells. The MAPK1 desitometric analysis of three experiments showed no significant change 
after 48h and 72h by KRAS reduction. The data suggested that inhibition of KRAS has no 
significant effect in either cell lines for MAPK1 (Fig.27B&E). 
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To analyse the activation of the NF-κB pathway, cell lysates were analyzed for changes in the 
level of total IκBα (subunits of NF-κB), as phosphorylation of the p65 subunit and the 
degradation of IκBα are known to be associated with activation of the NF-κB classical pathway 
(Hayden and Ghosh 2008). However, inhibition of KRAS expression by siRNA affects 
significantly the levels of IκBα in Caco2. Our results revealed that after 48h of transfection, it 
reduced IκBα protein level to 46% and ~ 70% after 48h and 72h respectively. Furthermore, a 
non-significant decrease in DLD1 was also detected after KRAS gene knockdown (Fig. 
27C&F). 
 
Figure 27:  Effect of MAPK1 and IκBα protein expression in DLD1 (A) and Caco-2 cells (D) 
after KRAS knockdown. Proteins (20μg) from whole-cell lysates were size-fractionated by 
SDS-PAGE under transferred on to membranes, and incubated with antibodies as indicated. 
A and D, representative Western blots of MAPK-1 (44kDa) and IκBα (41kDa) proteins in 
DLD1 cells (A) and Caco-2 cells (D). B, C, E & F desitometric analysis of MAPK-1 and IκBα 
proteins in DLD1 cells and Caco-2 cells. Proteins were densitometrically quantified and 
expressed as percent increase or decrease compared with scrambled controls. Equal loading 
of total proteins were ensured by ß-Actin (43kDa). Data presented are the means ± SEM of 
3 independent experiments with double confirmation. * corresponds to p  0.05.  
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5.  Discussion 
 
The crypt-villus axis of the intestinal mucosa is composed of a dynamic cell population in 
perpetual transition from a proliferative, undifferentiated stage to mature surface villus 
epithelial cells. The migration from the crypt base to the surface of the colon is accompanied by 
cellular differentiation that leads to important morphological and functional changes. The cell 
lines used in this study have similar characteristics to some cells of the crypt-villus axis. Caco2 
cells were previously described to possess characteristics of normal small intestinal epithelium 
(Jumarie and Malo 1995), HT-29 and DLD1 cells are known to possess the characteristics of 
surface villus cells (Panja et al. 1998).  
The main aim of the study was to understand the influence of CRC-mutations (KRAS and 
BRAF) in view of the regulation and induction of inflammatory cytokines and chemokines and 
to find the signaling mechanism controlling these changes in colorectal carcinoma cell lines. 
(CRC). Pro-inflammatory cytokines are probably released by sub-mucosal immune cells of the 
tumor microenvironment or/and tumor cells themselves, which can further enhance the 
expression of inflammatory chemokines and respective transcription factors important for cell 
proliferation, angiogenesis and migration. The maintenance of a pro-oncogenic 
microenvironment regulated by the tumor-promoting cytokine – chemokine axis, might vary 
according to the underlying oncogenic driver mutation (i.e. KRAS). Therefore, it was further 
part of study to investigate how these cytokines affect the chemokine regulation in the KRAS 
mutated and non-mutated cell lines in the presence or absence of the KRAS gene. In addition, a 
comparative mutational analysis was conducted to validate the previously published mutations 
(KRAS and BRAF) in CRC cell lines.  
5.1 Identification of Mutations in the Colorectal Cell lines.  
KRAS and BRAF mutations occurs in CRC therefore, in the present study KRAS Codon (12, 
13, 61 and 146) and BRAF (V600E) were systematically examined for all the mutations in the 
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RAS/RAF pathway through RFLP and real time PCR in six colorectal carcinoma cell lines. Our 
initial goal was to analyse the mutations in the different cell lines. The PCR/RFLP method is 
simple and has a higher reproducibility than the other techniques. However, the technique is 
highly specific, noninvasive, and cost-effective, and should provide a more sensitive and 
specific results for mass screening of CRC.  
The presence of KRAS mutation in histologically normal colonic mucosa has been described 
(Carvajal-Carmona et al. 2007). The KRAS mutation has been reported in approximately 40% 
of CRCs. 90% of the KRAS mutated CRCs have a mutation in codon G12D and G13D. Next to 
these mutations, the less frequent mutations at codon A61T and A146T were also analysed for 
the six CRC cell lines. The DLD1 cell line showed a G13D KRAS mutation. However, the 
other five cell lines did not show a mutation in the KRAS gene (Table 5). Previous studies 
demonstrated that expression of mutated KRAS alleles could increase tumor metastasis in 
human cell line model systems (Nakano et al. 1984;Pulciani et al. 1982). Targeting activated 
KRAS could inhibit tumor growth in colon cancer cell lines (Ross et al. 2001). 
In fact, KRAS is the central mediator of epidermal growth factor receptor (EGFR) signaling. 
Hence, the KRAS mutational status modifies the response of a tumor to anti-EGFR therapy 
(Feng et al. 2007). Two major key pathways RAS/RAF/MAPK and PI3K/AKT are known in 
CRC-cell lines which are immediately downstream of the EGFR, targeting the nucleus to drive 
cell proliferation, survival, angiogenesis, metastasis and invasion. The inhibition of either 
pathway could further strengthen the effect of EGFR inhibitors. Among them, targeting the 
RAS/RAF pathway is the most common (Servomaa et al. 2000). The mutations in this pathway 
lead to constitutive activation of the RAS oncoprotein in a guanosine triphosphate–bound state. 
The localization of activated RAS on the inner surface of the plasma membrane stimulates a 
series of subsequent signaling events leading to cellular proliferation. It is also mentioned that 
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targeting single Ras has been difficult, with more failures than successes, especially in gastro-
intestinal malignancies including colorectal cancer (Bos 1989). 
In our studies, the BRAF mutation V600E was confirmed in two cell lines HT-29 and Colo-205 
through ARMS primer-PCR, whereas the other four cell lines did not show the BRAF 
mutation. It is known that the BRAF V600E mutation is several folds more oncogenic 
compared to wild type BRAF (Davies et al. 2002b). In the active form, GTP-bound Ras recruits 
Raf protein to the cell membrane and binds it directly, activating Raf kinase. The Raf then 
phosphorylates and activates downstream mediators of cell growth and proliferation, including 
mitogen-activated protein kinase (MEK-1, 2), ERK1 and ERK2 (Nagasaka et al. 
2004;Wellbrock et al. 2004). It was previously shown that in CRC, BRAF mutations have been 
described in approximately 10% of tumors, and a recent study suggests that BRAF mutation is 
found in those tumors, not harboring KRAS mutations (Nagasaka et al. 2004). Thus, signal 
activation may occur through mutation in either BRAF or KRAS. In theory, direct inhibition of 
Raf could inhibit growth of tumors driven by mutations of either Raf or Ras (together 
accounting for more than 40% of CRC) (Nagasaka et al. 2004).  
 
 




Figure 28: Schematic illustration of pathway alterations involved in the development of 
CRC. The cardinal molecular genetic changes include somatic mutations in KRAS, BRAF, 
and occasionally ERRB2 (encoding Her2/Neu) and PIK3CA. The mutated gene products 
constitutively activate the signaling pathways that regulate cellular proliferation and 
survival and promote tumor initiation and progression. Adapted from (Kurman and Shih 
2011). 
 
5.2 Basal expression of cytokines and their receptors in mutated and wild 
type cell lines.  
 
The CX-1 cell line was excluded for further experimentation due to its highly metastatic nature 
(Meterissian et al. 1993) and different growth properties including non-adherent nature. 
Experiments were continued with two wild type cell lines i.e Caco2 and Colo-320, as well as 
the mutated CRC cell lines DLD1 (KRAS), HT-29 (BRAF) and Colo-205 (BRAF). 
The tumor microenvironment consists of tumor, immune, stromal, and inflammatory cells 
which produce cytokines, growth factors, and adhesion molecules that promote tumor 
progression and metastasis. A panel of basal cytokines (TNFα, IL-1ß, IFNγ and IL-6) and 
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cytokine receptors, which are more commonly involved in the tumor control and progression in 
colorectal carcinoma cell lines, was evaluated. 
Significant differences were observed for basal TNF-α and IL-1β expression between mutated 
(KRAS and BRAF) and non-mutated CRC cell lines. A pro- as well as anti-cancer role of TNF 
has been described (Dalum et al. 1999). This anticancer effect is multi-factorial as TNF can 
cause vascular necrosis, a direct apoptotic effect on the cells and also free radical induced cell 
death. Gene expression of TNFα was found to be the lowest in KRAS and BRAF mutated cell 
lines compared to non-mutated.  Based on these data, it could be suggested that a reduction in 
TNF-α level could be related to cell necrosis and apoptosis in mutated cell lines compared to 
wild type cell lines of CRC. In other words, reduction in TNF expression is probably necessary 
for mutated cells to survive. 
Similar results were obtained for IL-1β basal expression with an exception of BRAF mutated cell 
lines which showed an induction of IL-1β compared to KRAS mutated or non-mutated cell lines. 
Of particular interest in this setting is interleukin-1 (IL-1), a pleiotropic cytokine with 
numerous roles in both physiological and pathological states. It is known to be up regulated in 
many tumor types and has been implicated as a factor in tumor progression via the expression 
of metastatic and angiogenic genes and growth factors (Lewis et al. 2006a). 
A number of studies have reported that high IL-1 concentrations within the tumor 
microenvironment are associated with a more virulent tumor phenotype. In colon tumors, IL-1 
has been shown to be up regulated and patients with IL-1 producing tumors have generally bad 
prognoses (Lewis et al. 2006b). Similarly, in our data, the most pronounced expression of IL-
1β was detected in BRAF mutated cell lines and it is reported that patients with BRAF 
mutation have a bad prognosis. It shows that our data are in accordance with the clinical 
setting. 
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Strikingly, no gene expression of IFNγ and IL-6 was not detected in any of studied cell lines at 
basal level. However, IFNγ and IL-6 cytokines receptors were detected, as were TNFα and Il-
1β receptors at basal level. The presence of the receptors points to a functional cytokine 
sensitivity. A role of IL-6 in tumor progression has already been described (Waldner et al. 
2012). In fact, IFNs are proteins involved in many functions including, apoptosis, control of 
cell cycle and mediators of other cytokines (Gough et al. 2008;Slattery et al. 2011). IFN-γ is 
known for anti-proliferative and furthermore anti-tumor activity in CRC (Schroder et al. 2004). 
The lack of detection of these main pro-inflammatory cytokines in any of studied cell lines 
could explain that tumor cells are able to promote their microenvironment according to their 
needs. A regulation of apoptosis-related genes by IFNγ has been reported and IFNγ has also 
been hypothesized to regulate cell sensitivity to apoptosis (Tekautz et al. 2006). Additionally, 
IFNγ might induce the anti-tumorigenic role of TNF and thus to overcome the resistance of 
metastatic colon tumor cells to the TNF-induced classic apoptosis pathway (Liu et al. 2011a). 
Reduced expression of TNFα in mutated cell lines and the complete abolishment of IFN-γ 
expression in our data could be associated with increased tumor progression as has been 
suggested above.  
5.3 Basal and cytokine induced expression of chemokines in mutated and 
wild type cell lines.  
Chemokines are known to attract leukocytes during stress conditions (Mackay 2001) and  
promote tumor development (Mukaida and Baba 2012). Carcinogenesis of colon cancer has been 
correlated with mutation of the RAS/RAF family of genes in the MAP kinase pathway, 
suggesting the importance of mutation of these genes in the early stage of malignant 
transformation in colon cancer (Rajagopalan et al. 2002b). Mutations of KRAS/BRAF have been 
identified in many colorectal cancer cell lines, but the correlation with cytokine-mediated 
expression of chemokines by intestinal epithelial cell lines has not been studied.  
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In the current study, the regulation of pro- (CXCL1, CXCL8) and anti-angiogenic (CXCL10) 
CXC-chemokines was studied by RT-PCR. The expression of CXCL1 and CXCL8 was found to 
be highest in KRAS and BRAF mutated cell lines as compared to wild type (Caco2 and Colo-
320) cell lines at mRNA level. However, CXCL10 basal expression was highest in wild type as 
compared to KRAS and BRAF mutated cell lines. Previously, CXCL1 protein secretion was 
found to be enhanced in highly metastatic cell lines as compared to a cell line with low 
metastatic potential with the wild type Caco2 cells having shown the lowest CXCL1 levels (Li et 
al. 2004). This is in accordance with our results. Recent studies have also shown a basal 
difference of chemokine expression in intestinal epithelial cells of normal and IBD patients. It 
was suggested that the differences in the basal expression of CXCL1, CXCL8 and CXCL10 in 
the cell lines mimic in vivo conditions of normal intestinal epithelium (Banks et al. 2003). 
Moreover, in the tumor microenvironment, the balance between pro-and anti-angiogenic 
chemokines may determine the degree of angiogenesis and the ensuing tumor progression. 
Accordingly, I observed a reduced expression of the anti-angiogenic chemokine CXCL10 in wild 
type compared to mutated cell lines. The opposite was true in case of pro-angiogenic chemokines 
(CXCL1 and CXCL8). Indeed, the difference in basal chemokine expression could be due to the 
activation of transcription factors responsible for the expression of these chemokines. 
In addition to the basal chemokine expression, the obtained results showed that cytokine 
stimulation differentially influences the induction of target chemokines in the mutated (KRAS 
and BRAF) and non-mutated cell lines, suggesting the activation of differential or/and multiple 
pathways. TNFα and IFNγ were the main inducers for CXCL1, CXCL8 and CXCL10 gene 
expression in mutated cell lines compared to wild type (Caco2) cell line. However, an exception 
was observed for CXCL8 which showed a higher induction in wild type than in mutated cell 
lines after IL1β administration.  
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Another major finding was the observation that specific knockdown of mutant and wild type 
KRAS through siRNA disrupts chemokine gene expression. Specific siRNA inhibition of the 
KRAS gene in a KRAS-mutated cell line (DLD1) showed reduced gene expression of CXCL1 
and CXCL10 whereas the opposite was found in case of a wild type cell line Caco2. These 
results clearly show that mutation of the RAS gene in colon cancer influences gene regulation 
of chemokines, which is in accordance to previous reports. A previous report stated a reduced 
expression of chemokines after mutant KRAS inhibition in a human cancer cell line 
(Cunningham et al. 2004). Furthermore, a stable knockdown of oncogenic KRAS led to 
reduced proliferation rates and anchorage independent growth in lung adenocarcinoma cell 
lines (Sunaga et al. 2011). It suggests that mutant KRAS may affect the chemokine levels by 
shifting to additional pathways. Increased chemokine levels mean increased recruitment of 
inflammatory cells which are known to play a role in tumor growth and metastasis (Hingorani 
et al. 2003;Milne et al. 2009;Schubbert et al. 2007).   
As for  increased levels of chemokines and cytokines in tumor tissues a role in tissue 
remodelling and angiogenesis has been documented (Coussens and Werb 2002;Karin 2006;Sica 
et al. 2008), our study could give insight to this process as KRAS-mutation may lead to an 
increased tumor growth or metastasis by enhancing the recruitment of inflammatory cells. 
Further studies are required to explore the molecular mechanism controlling this process. In 
fact, previous studies on human cancers have shown a complex chemokine network that 
regulates the extent and phenotype of the infiltrating leukocytes, as well as the an effect on 
tumor growth, survival, migration, and angiogenesis (Balkwill 2004a). The pattern of 
chemokine-receptor and ligand expression in a tissue is generally correlated with the numbers 
and types of infiltrating cells that are present in the tumor microenvironment (Balkwill 
2004b;Karin and Greten 2005;Rossi and Zlotnik 2000;Sica et al. 2008).  
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On the other hand, these chemokines may promote tumor progression and invasion by 
stimulating the process of neo-angiogenesis and the activation of matrix proteases (Murphy, 
2001; Strieter et al., 2006). Previous studies have shown a role of cytokine-induced up-regulation 
of CXCL1 and CXCL8 for tumor growth and angiogenesis (Dhawan and Richmond 
2002;Haghnegahdar et al. 2000;Wang et al. 1998). In our findings TNFα strongly induced 
CXCL1 mRNA and protein expression in DLD1 KRAS mutant cell line in comparison with 
BRAF and wild type. Further analysis of cytokine receptors in this work illustrated the possible 
effect of mutation in the cell lines. We found that TNFα Rec1 and IFNγ Rec1 up-regulation in 
the BRAF mutated cell lines could cause deviation from the RAS-RAF pathway in inducing the 
cell lines.  
Higher expression of IFNγ Rec1 in BRAF mutated cell lines was demonstrated in a study that 
IFNγ sensitizes human colon carcinoma cells to TRAIL-mediated apoptosis due to caspase-8 
expression (Langaas et al. 2001). Here we can conclude that IFNγ Rec1 could play a role in 
activating cytokine pathway to induce the gene expression of cell lines. 
Furthermore, migration and invasion play important roles in the tumor-host interaction that 
contribute to the aggressiveness and metastatic potential of tumor cells (Liotta and Kohn 2001).  
 Up-regulation of CXCL8 has been recently linked to β-catenin activation. The study was based 
on microarray analysis of differentially expressed genes regarding normal and neoplastic colon 
(Peifer and Polakis, 2000). Therefore, the basal CXCL8 protein secretion in the current cell 
lines may be the result of a constitutively active β-catenin signalling pathway. 
Nevertheless, its underlying mechanisms and true impact on tumor progression are yet to be 
determined. The results of this study may be helpful to build a solid rationale for novel 
therapeutic interventions targeted to specific inflammatory molecules, and to identify novel 
prognostic CRC markers.  
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Figure 29:  Inflammation in angiogenesis and metastasis cytokines, chemokines and 
proteases (MMP) produced by inflammatory cells influence the processes of angiogenesis 
and metastasis. They alter the migratory properties and behaviour of cancer cells, degrade 
the extra cellular matrix (ECM), and increase the tumor’s blood supply and access to 
vasculature. Immune cells also create chemokine gradients that guide the migration of 
metastatic cells through the tissue to distant organs and facilitate other aspects of 
metastasis. Adapted from (Terzic et al. 2010). 
 
5.4 The Pathway studies (STAT3, NF-κB and MAPK1) in mutated and wild type 
 cell lines cell lines  
 
In order to find out the mechanisms involved in the induction of chemokines in mutated 
(KRAS) and wild type cell lines at basal level and after cytokines treatment, the basal 
expression of candidate transcription factors (MAPK1, NF-κB and STAT3) was analyzed. A 
marked difference in basal expression of the transcription factors was observed between the 
KRAS mutated and wild type cell line. In comparison to wild type, a constitutive expression of 
transcription factors in a KRAS-mutated cell line could suggest that mutation could 
independently influence the activation of these pathways which can be further enhanced by 
treatment of cytokines. 
A link between inflammation and colon cancer has already been established. Inflammatory 
cytokines can serve as tumor suppressors or tumor progressors as well as  survival factors, and 
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can promote tumor growth by promoting angiogenesis and suppressing immune-mediated 
tumor elimination (Karin and Greten 2005). They act through their transcriptions factors such 
as NF-κB, MAPK1 and STAT-3 (Duyao et al. 1992;Terzic et al. 2010). 
A large fraction of CRC tumors and cell lines exhibit constitutive activation of transcription 
factors that are essential components of multiple inflammatory pathways, namely nuclear factor 
kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) (Popivanova 
et al. 2008;Terzic et al. 2010;Vallabhapurapu and Karin 2009) and MAPK (Terzic et al. 
2010;Kreeger et al. 2009). 
MAPK is an important transcription factor in the inflammatory signaling pathway (Cohen et al. 
2005). The primary function of Raf is to phosphorylate and activate MEK (also MAP-kinase 
(MAPK) (Cobb and Goldsmith 1995). MEK, in turn, catalyzes the phosphorylation of ERK1 
and ERK2 (MAPKs), the only known substrates for MEK phosphorylation. Phospho-ERK (p-
ERK) then dimerizes and translocates to the nucleus where it leads to transcription-factor 
activation and cell proliferation, differentiation, survival, invasion, and metastasis (Sebolt-
Leopold and Herrera 2004). MAPK is constitutively activated with high frequency in colon 
cancers (Hoshino et al. 1999). Thus, the ERK/MAPK step of the transcription activation 
pathway may represent an important therapeutic target, given its position as the final common 
pathway for cell proliferation and other activities relevant to cancer pathogenesis. In preclinical 
models it has been demonstrated that MEK inhibition via a small molecule inhibitor results in 
cell death (Wang et al. 2004). This effect is most pronounced in p-53 wild-type cells, where it 
is postulated that tumor cells may be more dependent on MEK/MAPK signaling for cell 
survival in the presence of intact p53(Shaw et al. 1991;Terzic et al. 2010).  
NF- B, one of the major transcriptional regulators of many genes, is known to be highly 
activated in colon cancer (Yeruva et al. 2008a) by cytokines like TNF through its receptors 
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(TNFR) (Waldner and Neurath 2008). It has been  demonstrated  that several TNFR members 
translocate into the nucleus to interact with different NF-κB Rel subunits and activate the 
transcription of NF-κB target genes (Locksley et al. 2001).  NF-κB acts through either the 
classical or the canonical pathway (Yeruva et al. 2008a). 
In chronic inflammation, cytokines and chemokines produced by inflammatory cells, propagate 
a localized inflammatory response and also enhance the survival of premalignant cells by 
activating NF-κB (Lin and Karin 2007).  Activation of the IKK/ NF-κB pathway is one key 
survival mechanism in a variety of cancer types (Karin and Greten 2005;Schulze-Bergkamen 
and Krammer 2004;Yeruva et al. 2008b). Numerous studies have indicated that NF-κB can 
block apoptosis by regulating the anti-apoptosis proteins such as inhibitor of apoptotic proteins 
(IAPs) (Kucharczak et al. 2003). Another mechanism whereby NF-κB may inhibit apoptosis is 
through its ability to inhibit prolonged c-Jun N-terminal kinase (JNK) activation and 





Figure 30: Canonical and non canonical NF-κB activating pathways. Source: Inhibition of 
tumor growth by NF-kappa B inhibitors. Adapted from (Umezawa 2006)   
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NF- B activation in intestinal epithelial cells is also a major regulator of chemokine gene 
expression (Yeruva et al. 2008b). A number of studies have revealed that LPS induced 
cytokines like IL-1  and TNF  change the expression of several chemokines through the 
transcription factor NF- B in IECs (Elewaut et al. 1999;Kim et al. 2004;Kim et al. 2002;Vallee 
et al. 2004;Yeruva et al. 2008b). NF- B is a complex transcription factor which consists of 
several subunits. The degradation (reduction) of I Bα-level and the activation of p65 subunit is 
known as classical NF- B pathway (Karin and Greten 2005). Several inhibitors are present 
which inhibit NF- B activation (Kim et al. 2002). Some of them are non specific and some are 
specific inhibitors. A previous study reported that inhibition of NF- B (p65) reduces 
chemokine gene expression which could imply a pharmacological importance in treating IBD 
(Yeruva et al. 2008b) . These results are in accordance with our study, where inhibition of 
KRAS by the siRNA approach induced NF- B (reduced I Bα-level) followed by an increase in 
chemokine gene expression in the wild type cell line.  
STAT-3 is a down-stream target in the IL-6 pathway. A striking finding of the current study 
was the detection of its phosphorylation by IFNγ treatment in KRAS mutated DLD1. The role 
of STAT-3 as pro- or anti-tumor agent has been controversially documented. STAT3 was 
shown to be repeatedly activated in many types of human solid and blood cancers, including 
colon cancer (Buettner et al. 2002;Corvinus et al. 2005;Kusaba et al. 2005;Ma et al. 
2004;Turkson and Jove 2000), however its phosphorylated form (p-STAT-3) has not been 
evaluated so far in this setting.  
In mouse models of colitis-associated cancer (CAC) and liver cancer, the genetic and 
pharmacological manipulation of NF-κB and STAT3 activation has revealed the complex 
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interaction of the signaling cascades in various cell types and that tumor cells have intrinsic and 
extrinsic mechanisms to regulate apoptosis and proliferation (Eaden et al. 2001). 
Previous studies have shown that blocking the signaling to STAT3 inhibits cancer cell growth, 
indicating that STAT3 is crucial to the survival and growth of tumor cells (Buettner et al. 
2002;Ling and Arlinghaus 2005;Turkson and Jove 2000) and is an attractive therapeutic target 
for cancer. In fact, a main effort to target constitutive STAT3 signaling was focused on a 
multitude of cancer cells. Whilst it has been shown that is activated in colon cancer–initiating 
cells, no approach has been initiated to explore the STAT3 as a possible therapeutic target in 
colon cancer–initiating cells.  
However, STAT3 has also been shown to have tumor suppressor role depending on the 
mutational background of the tumor (de la Iglesia et al. 2008). Accordingly, we could show a 
lower expression in WT compared to KRAS colon cancer cell lines. 
In our studies, we further showed that elevated p-STAT3 is detected in the DLD1 (KRAS) 
colon cancer cell line and can be further induced by IFNγ. We could however show, that at 
basal level, colon cancer cell lines do not express IFN  nor IL-6 (another upstream inducer of 
the STAT-3 pathway). Thus, the STAT-3 pathway might be switched down in wild type CRC-
cell lines, whilst in KRAS mutated cells, it takes on pro-tumorigenic roles. 
These results suggest that activated STAT3 is indeed a novel therapeutic target, especially in 
KRAS mutated, colon cancer–initiating cells. Previous studies showed that, co-operation 
between IFN  induced STAT1 and that the constitutive or inducible NF- B is necessary for the 
transcriptional activity of IFN inducible chemokines (Hiroi and Ohmori 2003).  
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This work illustrates, that tight regulation of cytoplasmic with nuclear transcriptional processes 
is necessary, and that external stimuli affect by i.e. cytokines can affect intra-cellular processes, 
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